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Appendix S2. Additional description of methods. 
 
Settings 
We conducted two cohort studies using study data from the UK (January 1997 to July 
2017) and Denmark (January 1997 to December 2016). Both countries have publicly 
funded health care systems with universal health coverage [1, 2].  
In the UK, we used the primary care data from the Clinical Practice Research Datalink 
(CPRD) Gold [3], with linked data from the Office for National Statistics (ONS) (deaths), 
Hospital Episode Statistics (HES) (hospital admissions), and the Index of Multiple 
Deprivation (IMD, socioeconomic deprivation). 
In Denmark, we used data from nationwide registries on demographics, civil and vital 
status (Civil Registration System) [4], hospital contacts including inpatient stays, 
outpatient hospital clinic visits, and emergency department visits (Danish National 
Patient Registry) [5], and education duration (Danish Education Registries) [6]. Data 
were linked using the unique personal identifier assigned to all Danish residents at birth 
or upon immigration. We endeavoured to make the UK and Danish cohort studies as 
similar as possible to ensure comparability (see details of data sources in Appendix S4). 
Couple identification  
In the UK, we used the CPRD to identify partners using a previously developed 
algorithm [7-11]. We defined study initiation as the latest of the date an individual’s GP 
practice met CPRD quality control standards or the study start date. In each household, 
we identified an opposite-sex couple with an age gap of ≤10 years and no person in the 
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same household aged within 15 years of either member of the couple on the study 
initiation date. We excluded couples in which both partners were <40 years or ≥95 years; 
in which either partner had a record of a morbidity code indicating residence in a 
communal establishment; or couples in households with >10 registered members. 
In Denmark, we identified partners using an algorithm developed by Statistics Denmark 
that uses unique personal identifiers and determines partnership status (spouse/partner) 
by considering information on civil status, demographics, address, and close kinship 
(e.g., parents, siblings, and children) [12].  
Matched study population 
Among eligible couples, we identified bereaved people (exposed) when their partner 
died. The date of bereavement was defined as the index date. In the UK, we obtained 
dates of death from ONS when available (59.8%) and from CPRD for individuals not 
linked to ONS (40.2%). In Denmark, we used death dates from the Civil Registration 
System. 
We then matched each bereaved person to up to 10 non-bereaved partners (sampling 
with replacement) on age (within 1 year), sex, and county of residence (Denmark) or 
general practice (UK) on the index date. Individuals were only included in the 
comparison cohort if they had not experienced partner bereavement on or before the 
index date of their matched bereaved person. We excluded all individuals who died on 
the index date as they did not contribute person-time. We also excluded all individuals 
with a diagnosis of a relevant outcome (urticaria, alopecia areata, or vitiligo) before the 
index date. We required all study participants to have ≥1 year of healthcare registration 
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history prior to the index date in the UK, to allow adequate time for recording covariates 
and history of outcomes of interest. Details of the exclusion criteria are presented in 
Appendix S5. 
Outcomes 
In the UK, we identified chronic urticaria, alopecia areata, and vitiligo using relevant 
morbidity codes recorded in in primary (Read codes) or secondary care (International 
Classification of Diseases, Eighth and Tenth Revisions [ICD-8 and ICD-10] codes), and 
diagnostic algorithms (Appendix S5). Code lists are available for download: 
https://datacompass.lshtm.ac.uk/1544/ (UK) and Appendix S6 (Denmark). We followed 
all participants from their index date until diagnosis of a specific outcome (urticaria, 
alopecia areata, or vitiligo), date of last data collection from primary care practice (UK), 
transfer out of the practice by either member of the couple (UK), emigration of either 
member of the couple (Denmark), death, or the study end date, whichever occurred first. 
If an individual in the comparison cohort experienced bereavement, he/she was 
censored one day before bereavement and subsequently included in the bereaved 
cohort (Figure S1). 
Covariates 
As possible confounders, we included comorbidities (original Charlson Comorbidity 
Index (CCI) score) [13], lifestyle covariates (smoking and alcohol consumption), body 
mass index (BMI), and socioeconomic status (quintile of IMD [UK] and education 
duration [Denmark]) (Appendix S5).  
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We hypothesised that the level of stress associated with bereavement depends on 
whether a partner’s death was unexpected. We therefore stratified the estimates by the 
degree to which the partner’s death might be considered unexpected based on 
comorbidity level for the partner who died. We computed an age-adjusted CCI score 
based on comorbidities recorded up to one month before death of deceased partners. 
The age-adjusted CCI assigns 0 to 6 points to a range of chronic diseases according to 
their ability to predict death, with additional points given according to age [13]. Based on 
the total score, we classified the risk of partner death as low (0–3 points), intermediate 
(4–6 points), or high (≥7 points). As an alternative measure, we identified presence of 
terminal disease among partners as recorded before the date of death. 
Statistical analysis 
We used stratified Cox regression to estimate hazard ratios (HRs) with 95% confidence 
intervals (CIs) for chronic urticaria, alopecia areata, and vitiligo comparing those who 
were bereaved to those who were not bereaved. In the main analysis, we examined 
associations for the entire follow-up period. As we hypothesized that the effect of 
bereavement would be most pronounced during the short-term [10], we further 
examined the associations by time since the index date (for alopecia areata and vitiligo: 
0–30 days, 0–90 days, 0–365 days, and 0–1095 days; for chronic urticaria: as our 
definition required two codes recorded six weeks apart, we categorised the follow-up 
time as 0–182 days, 0–365 days, and 0–1095 days). We initially constructed an 
unadjusted model stratified by matched set to account for the matching variables. In a 
second model, we additionally adjusted for CCI. In the fully-adjusted model, we further 
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adjusted for education duration (Denmark), IMD status (UK), BMI (UK) and lifestyle 
variables (UK).  
In each setting, we stratified the main analysis by age, sex, and risk of partner death 
(deceased partner’s age-adjusted CCI score and presence of terminal disease). We 
used likelihood ratio tests to explore possible effect modification by these characteristics.  
We undertook complete-case analyses in the fully-adjusted models, which would be 
unbiased under the assumption that missingness was not associated with the outcome, 
conditional on the other variables. As lifestyle data are unlikely to be missing at random 
and we lacked data on probable predictors of missingness, imputation techniques were 
not appropriate for correcting potential biases [14]. We further investigated patterns of 
missingness using conditional logistic regression. In addition to fitting the unadjusted 
and adjusted models using the full sample, we also fitted the models on the sub-cohort 
without missing covariate data (complete-case subcohort) to allow comparison with the 
fully-adjusted model.  
We assessed the assumption of proportional hazards for the overall study period and 
each specific time period by visual inspection of log-log plots. We further evaluated 
whether the HRs changed over time by stratifying the follow-up period since 
bereavement (0–182 days, 183–365 days, 366–1095 days, 1095+ days for chronic 
urticaria; 0–30 days, 31–90 days, 91–365 days, 366–1095 days, 1095+ days for 
alopecia areata and vitiligo).  
We conducted several sensitivity analyses to test the robustness of the results (Table 
S1). All study analyses were pre-planned unless otherwise stated. We conducted all 
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analyses separately for the UK (using Stata/MP 15.1) and Denmark (using SAS 9.4). 
We combined the main results (from the adjusted models) in Stata using DerSimonian 
and Lairds’ random-effects model [15].  
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Appendix S3. Additional description of results of additional and sensitivity 
analyses 
 
Results 
Patient characteristics 
Figure S2 shows the study flowchart. Median age was approximately 74 years in the UK 
and 71 years in Denmark. Two-thirds of participants were women in both settings (Table 
S2). In both countries, bereaved individuals had a higher comorbidity burden, were 
more deprived (UK), more likely to be current smokers (UK), ex-drinkers (UK), obese 
(UK), and to have a shorter education duration (Denmark) than the non-bereaved 
comparison cohort at index date (Table S2).  
Chronic urticaria 
The pooled HR (adjusted for study participants’ CCI scores) for the association between 
partner bereavement and chronic urticaria was 0.95 (95% CI, 0.85–1.07) (Figure S3). 
The number of events for chronic urticaria within 0–182 days since partner bereavement 
in both settings was small (Table S3). We observed no evidence of differences in risk of 
chronic urticaria within 0–365 days (HR 0.85, 95% CI, 0.55–1.31) or 0–1095 days (HR 
0.87, 95% CI, 0.67–1.15) after bereavement (Figure S3). 
Alopecia areata 
The pooled HR (adjusted for study participants’ CCI scores) for the association between 
partner bereavement and alopecia areata was 0.90 (95% CI, 0.73–1.12) (Figure S3). 
Very few events occurred within 0–30 days, 0–90 days and 0–365 days in either setting 
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(Table S3). We observed no evidence of higher HRs for alopecia areata within 0–1095 
days (HR 1.01, 95% CI, 0.73–1.40) after bereavement. 
Vitiligo 
The pooled HR (adjusted for study participants’ CCI scores) for the association between 
partner bereavement and vitiligo was 0.90 (95% CI, 0.74–1.10) (Figure S3). Very few 
events occurred within 0–30 days and 0–90 days since partner bereavement in either 
setting (Table S3). We observed no evidence of higher HRs for vitiligo associated with 
partner bereavement within 0–365 days in the UK (HR 1.30, 95% CI, 0.84–2.02) but 
were unable to estimate a reliable association using Danish data due to small number of 
events (Table 1). Similarly, we observed no evidence of a higher HR for vitiligo within 0–
1095 days (HR 0.90, 95% CI, 0.47–1.75) after bereavement. 
Subgroup analyses 
Figure S4 and Tables S4-6 show the results of subgroup analyses by age, sex, and risk 
of partners’ deaths for the entire follow-up period. For vitiligo, there was some evidence 
suggesting that the HR differed by sex (with a lower HR among men) in the UK. We did 
not observe substantial differences across other subgroups. 
Additional analyses and sensitivity analysis 
In the UK, missingness of lifestyle data was dependent on each outcome, conditional on 
bereavement status and other covariates (Table S7). However, HRs for the whole 
cohort and for the complete-case cohort were similar in unadjusted and adjusted 
models in both settings (Table S8). Some log-log plots did not show parallel lines 
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between bereaved and comparison persons, suggesting non-proportional hazards over 
time for chronic urticaria in Denmark and for vitiligo in the UK (Figure S6). We further 
investigated changes in HRs during several stratified follow-up periods (Table S7) and 
observed no significant difference in hazards for all outcomes in the UK. We found a 
lower HR for vitiligo (0.55, 95% CI, 0.07–4.14) within 0–30 days, and higher HRs within 
31–90 days (2.05, 95% CI, 0.70–6.02), within 91–365 days (1.30, 95% CI 0.79–2.12), 
and within 366–1095 days (1.11, 95% CI, 0.76–1.62), and a lower HR after 1095 days 
since bereavement (0.56, 95% CI, 0.39–0.81) in the UK with wide CIs. We found a 
higher HR for alopecia areata within 366–1095 days (1.93, 95% CI 1.13–3.31), and a 
lower HR after 1095 days since bereavement (0.93, 95% CI 0.64–1.35) in Denmark. 
Results of all sensitivity analyses were similar to those of the main analysis (Tables 
S10–17). 
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Appendix S4. Additional discussion of results. 
 
Based on routinely collected data in the UK and Denmark, our study showed no overall 
increased risk of chronic urticaria, alopecia areata, or vitiligo following partner 
bereavement.  
Comparison with other studies 
Limited prior epidemiological studies have investigated the association between stress 
and chronic urticaria. Consistent with our study, a 2018 case-control study did not find 
differences in the number of stressful life events during the past 12 months when 
comparing patients with chronic urticaria with controls [1]. The stress level was 
measured using the Social Readjustment Rating Scale [2], in which partner 
bereavement is considered as the most stressful item. However, only women were 
included, thus limiting the generalisability of study findings. In contrast, two cross-
sectional studies reported that 16%-33% of patients with urticaria had experienced prior 
stressful life events [3, 4], most commonly the death of a close family member [4]. 
Notably, associations could not be established due to the absence of a control group [3, 
4]. In a Taiwanese study, patients with chronic urticaria had more major life events 
during last 6 months, compared with controls, based on a semi-structured questionnaire 
[5].  
Similar to chronic urticaria, current epidemiological evidence for an association between 
stress and alopecia areata is contradictory [6-12]. Only one case-control study [7] 
reported an increased risk associated with stressful life events in the past year, 
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measured using the Social Readjustment Rating Scale [2]. Another case-control study 
reported no difference in risk associated with recent stress, but a higher score in the 
presence of certain prior stressful life events including loss of a family member during 
childhood and emotional neglect by relatives [6]. Our findings are consistent with a third 
study that found no difference in stress scores between alopecia areata cases and 
controls [8]. The stress score was measured using the Life Event Scale, which contains 
116 major life events including loss of spouse [13]. Further investigation showed that 
patients who attributed their illness to stressful life events reported more life events 
versus those who did not (mean difference 2.95) [8]. Similarly, four other studies 
reported no association between alopecia areata and psychological stress [9-12]. 
Unfortunately, low event rates of alopecia areata in our study limited our interpretation 
of the short-term effect of bereavement. Further investigation is needed to confirm our 
results. 
Regarding vitiligo, one study reported no difference in the number of stressful events 
between cases and controls [14]. However, three other studies reported an increased 
risk of vitiligo associated with stress [7, 12, 15]. Of these, one study demonstrated a six-
fold increased risk of vitiligo associated with stress [7]. In the UK setting, we observed a 
higher risk of diagnosing vitiligo in women but not in men. However, as men are less 
likely to present for a primary care consultation than women [16], we hypothesize that 
this sex difference is likely due to health-seeking behaviour rather than a protective role 
of bereavement in men. Another case-control study [15] observed more stressful life 
events, including death of spouse, among patients with vitiligo compared with controls, 
as measured by the Schedule of Recent Experience questionnaire [17]. However, 
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partner bereavement was not regarded as one of the 12 most frequently reported life 
events in the study [15]. A recent population-based matched cohort study also showed 
a significantly increased risk of vitiligo associated with stress-related disorders (HR 1.37) 
[12]. In our study, estimates were statistically imprecise in both settings, but a possibly 
increased risk of vitiligo associated with partner bereavement within 90 days in the UK 
was observed. 
This is the first study to investigate the associations between partner bereavement and 
chronic urticaria, alopecia areata, and vitiligo. It included analysis of two large 
population-based cohorts in settings with universal healthcare. Unlike previous studies 
using diverse stressful life events as the exposure, we used partner bereavement as an 
extreme stressor, to minimise heterogeneity in exposure to different types of stress. 
Moreover, as recording of death is of high quality in both databases, partner 
bereavement represented a reliable measure with a specific onset compared with other 
stressful life events. Importantly, we used data from two countries to validate our 
findings.  
Limitations 
We were unable to measure the level and duration of stress arising from bereavement. 
However, the death of a partner is considered extremely stressful in most cases. 
Secondly, we may have misclassified partnership status, particularly in the UK setting 
where direct data on relationship status are unavailable. Moreover, we could not identify 
changes in partnership over time in the UK. We used relatively strict criteria to identify 
partners to reduce potential misclassification bias. Even if such misclassification was 
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present, bereavement of a significant household member was captured, which is also a 
stressful life event. Further, we used Danish data containing detailed information on 
partnership status to complement the UK findings. It is important to note that in 
Denmark skin disease outcomes were recorded in a hospital setting, resulting in a 
potential delay between actual disease onset and diagnosis and more likely 
representing severe cases. In contrast, mild/moderate cases diagnosed in primary care 
were captured in the UK setting. Moreover, as data were available since birth in the 
Danish setting, medical history of urticaria, alopecia areata, and vitiligo diagnosed in a 
hospital setting during childhood might be more completely recorded than in the UK 
setting. In the UK setting, there is missingness of BMI and lifestyle covariates, but 
results from sensitivity analyses showed little difference from the main analysis, 
suggesting that missing data is unlikely to affect our results. Finally, people with mild 
skin conditions may be less likely to seek medical advice in the period shortly after 
bereavement as these skin conditions are not life-threatening. This bias may have led 
specifically to underestimation during the short-term follow-up period and an 
overrepresentation of the most severe skin diseases.  
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Appendix S5. Information on data sources. 
 
In the United Kingdom (UK) and Denmark, general practitioners coordinate all 
healthcare contacts, including referrals to specialists. 
UK 
We based the UK cohort study on data from the Clinical Practice Research Datalink 
(CPRD), Hospital Episode Statistics (HES), the Office for National Statistics (ONS), and 
the Index of Multiple Deprivation (IMD). 
The CPRD covers approximately 7% of the UK population--a representative sample 
with regard to demographics (age, sex, and ethnicity) [1]. We used data from the CPRD 
Gold July 2017 build, which contains 14,942,430 patients whose care met acceptable 
quality standards across 718 general practices. The CPRD contains prospectively 
collected primary care records from general practices documented using Vision 
Software. Anonymised data include recorded symptoms and diagnoses (coded using 
Read codes), written prescriptions (coded using British National Formulary codes), 
health-related behaviors (smoking and alcohol consumption), anthropometric data 
(height and weight), and referrals to specialists. Approximately 60% of participating 
practices registered in England have consented to link their patient records to other data 
sources, including the HES, ONS and IMD.   
The HES contains National Health Service inpatient hospital stay records in England, 
with linkage to the CPRD since 1997. Diagnoses are coded using the International 
Classification of Diseases, Tenth Revision (ICD-10), while procedures, including 
surgeries, are coded using the Office of Population and Censuses and Surveys (OPCS) 
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Classification of Interventions and Procedures codes, Version 4 [2]. Several diagnoses 
and procedures can be recorded for each care episode. Data on the order of diagnosis 
codes for a given episode are available, with the first-listed diagnosis typically 
constituting the main reason for admission. In the current study, the cohort used in the 
main analysis was not restricted to persons eligible for HES, because urticaria, alopecia 
areata and vitiligo are commonly diagnosed in the general practice setting. A sensitivity 
analysis restricted to cohort members with linked HES data was used to test the 
robustness of our results. 
The ONS contains death registration data. Most information is supplied by the informant 
(usually a close relative of the deceased). Deaths are to be registered within five days, 
and on average 78% of deaths are registered within this time frame. The death 
registration data used in our study included all deaths registered from 2 January 1998 to 
19 September 2017. Data on dates of death were available.  
The English Indices of Deprivation [3] are based on several indicators covering aspects 
of material deprivation (housing, employment, income, access to services, education 
and skills, crime [personal and material victimisation at local level], and living 
environment). The Index of Multiple Deprivation (IMD) is calculated as a weighted sum 
of the domain indices. For practices in England that have consented to participate in the 
linkage program, the patient postcode of residence is mapped to the 2001 “lower layer 
super output area” (LSOA) boundaries using a postcode lookup file. Practice-level 
linkage uses the practice postcode, which is linked via LSOA, SOA (Northern Ireland), 
or datazone (Scotland) to the most recent versions of the different national Indices of 
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Deprivation. Both the patient-level and practice-level IMD contains quintiles of 
deprivation (1=least deprived, 5=most deprived).  
Denmark 
Denmark (population 5.7 million inhabitants) has a long tradition of registering health 
and social data about the population in nationwide registries. For this study, we used 
information recorded in the Civil Registration System [4], the Danish National Patient 
Registry [5], and the Danish Education Registry [6].  
The Civil Registration System [4] contains computerised data on demographics, address, 
vital statistics, civil status, and identifiers of close relatives (spouse, children, and 
parents) for the entire Danish population since 1968. The Civil Registration System 
assigns a unique personal registration number to all Danish residents, which is used 
across the public sector to record information. This number enabled linkage of all data 
sources used in our study. We used the Civil Registration System to identify the study 
population, their partners, and vital status. 
The Danish National Patient Registry [5] is a hospital registry established in 1977. It 
provides complete nationwide coverage of non-psychiatric inpatient stays since 1978 
and psychiatric inpatient stays, outpatient specialty clinic (ambulatory) visits, and 
emergency room contacts since 1995. Each contact is registered with information on 
dates of admission and discharge or start and end of outpatient follow-up, the primary 
diagnosis (main reason for contact), optional secondary (contributory) diagnoses, 
surgical procedures, and certain non-surgical treatments and examinations. Diseases 
are recorded at discharge, outpatient contact, or surgery by the treating physician using 
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ICD-8 codes through 1993 and ICD-10 codes thereafter. We used the Danish National 
Patient Registry to identify comorbidities among members of the study cohorts and their 
deceased partners. 
The Population Education Registry [6] includes information on the highest educational 
level attained by residents. It is based on administrative records from educational 
institutions and is supplemented with self-reported information for persons who 
completed their education before 1974 and for immigrants schooled outside Denmark. 
In 2007, 3% of ethnic Danes born in the 1945-1990 period had missing data. This 
number was higher for immigrants (up to 15%). It may be unreliable for younger people 
who are less likely to have attained their highest educational level. 
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Appendix S6. Algorithms for identifying study outcomes and covariates. 
History of relevant study outcomes 
Partners who had any diagnosis of relevant study outcomes recorded before cohort 
entry were classified as having a history of the outcomes and were therefore excluded 
from the analysis. In the UK, we used Read codes and International Classification of 
Diseases, Tenth Revision (ICD-10) codes to identify diagnoses in CPRD and HES when 
available. We used ICD-8 and ICD-10 codes in Denmark. In the analysis of chronic 
urticaria, we identified urticaria history, including codes for inducible forms urticaria and 
angioedema. For alopecia areata, all non-specific codes (including non-specific 
descriptions of areata or ophiasis) were used as exclusion criteria. For vitiligo, we 
included codes both for vitiligo and for hypopigmentation in the UK (not applicable in 
Denmark). 
Study outcomes 
In the UK, we identified chronic urticaria, alopecia areata, and vitiligo using relevant 
Read codes in CPRD primary care records. We also used ICD-10 codes identified from 
HES hospital records when available. In Denmark, we used ICD-8 and ICD-10 codes to 
identify inpatient, outpatient hospital clinic, and emergency room primary or secondary 
diagnoses from the Danish National Patient Registry. 
In both settings, we defined chronic urticaria as at least two diagnoses recorded (on 
separate days) at least six weeks apart. The outcome date was identified as the second 
diagnosis. In Denmark, we excluded ICD-8 code “70890” and ICD-10 code “DL508D”.  
We defined alopecia areata and vitiligo outcomes as the first recorded diagnosis.  
Lifestyle and education duration covariates 
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In the UK, categorization of lifestyle variables (smoking status, body mass index, and 
alcohol consumption) was based pragmatically on the status recorded closest to the 
index date. Records within 1 year before to 1 month after the index date were regarded 
as the best, records within 1 month after the index date to 1 year after as the second 
best, the record nearest to 1 year before the index date as third best, and the record 
nearest to 1 year after the index date as least best. We mainly used Additional Clinical 
Details files in the CPRD to identify lifestyle variables. For smoking, we further used 
Read codes and prescribing records of smoking cessation treatment (nicotine 
replacement therapy) in the CPRD and ICD-10 codes in the HES. For alcohol 
consumption, we also used Read codes and prescribing records of alcoholism 
treatment in the CPRD and ICD-10 codes in the HES. For body mass index, we 
obtained height and weight measurements recorded in the CPRD and calculated body 
mass index (weight/height2).1 We defined body mass index according to World Health 
Organization guidelines (BMI: <18.5, 18.5–24.9, 25–29.9, and ≥30 kg/m2), alcohol 
consumption in the categories of current drinker, ex-drinker, and non-drinker, and 
smoking in the categories of current smoker, ex-smoker, and non-smoker. 
In Denmark, we used information on educational duration recorded at Statistics 
Denmark using the variable “hfaudd”, which follows the International Standard 
Classification of Education (ISEC). We categorised education as short (ISEC level 2; 
hfaudd=10), medium (ISEC level 3; hfaudd=20–39), or long (ISEC levels 4 and 5; 
hfaudd=40–89). Short education corresponds to basic compulsory schooling of 7–10 
years. Medium education corresponds to youth education, including general upper 
secondary school and vocational education and training (e.g., skilled craftsman) leading 
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to a total of 11–12 years of schooling. Long education of ≥13 years includes higher 
education, such as that leading to jobs as a programmer, primary school teacher, nurse, 
or physician. 
Comorbidity burden (variable for adjustment) 
We defined comorbidity burden on the index date using the Charlson Comorbidity Index 
(CCI), which assigns 0 to 6 points to a range of chronic diseases.2 CCI scores were 
categorized as low (0 points), intermediate (1–2 points), and high (≥3 points).  
Socioeconomic deprivation (variable for adjustment) 
In the UK, we used the quintiles of IMD as a measure of socioeconomic deprivation. 
When individual-level IMD status was missing, we used practice-level IMD. 
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Appendix S7. Code lists for defining partners’ risk of death, outcomes, and other 
covariates in Denmark. 
 
Age-adjusted Charlson Comorbidity Index and terminal disease 
Score 1 ICD-8 ICD-10a ATC 
   Myocardial 
infarction 
”410”  ”DI21” ”DI22” ”DI23”  
   Congestive heart 
failure 
”42709” ”42710” ”42711” ”42719” 
”42899” ”78249”  
 
”DI50” ”DI110” ”DI130” 
”DI132” 
 
   Peripheral 
vascular disease 
”440” ”441” ”442” ”443” ”444” ”445”  ”DI70” ”DI71” ”DI72” 
”DI73” ”DI74” ”DI77” 
 
   Cerebrovascular 
disease 
”430” ”431” ”432” ”433” ”434” ”435” 
”436” ”437” ”438”  
”DI60” ”DI61” ”DI62” 
”DI63” ”DI64” ”DI65” 
”DI66” ”DI67” ”DI68” 
”DI69” ”DG45” ”DG46” 
 
   Dementia “29009” “29010” “29011” “29018” 
“29019” “29309” 
“DF00” “DF01” “DF02” 
“DF03” “DF051” 
“DG30” 
 
   Chronic pulmonary 
disease 
“490” “491” “492” “493” “515” “516” 
“517” “518”  
“DJ40” “DJ41” “DJ42” 
“DJ43” “DJ44” “DJ45” 
“DJ46” “DJ47” “DJ60” 
“DJ61” “DJ62” “DJ63” 
“DJ64” “DJ65” “DJ66” 
“DJ67” “DJ684” 
“DJ701” “DJ703” 
“DJ841” “DJ920” 
“DJ961” “DJ982” 
“DJ983” 
 
   Connective tissue 
disease 
”712” ”716” ”734” ”446” ”13599”  
 
”DM05” ”DM06” 
”DM08” ”DM09” 
”DM30” ”DM31” 
”DM32” ”DM33” 
”DM34” ”DM35” 
”DM36” ”DD86” 
 
   Ulcer disease “53091” “53098” “531” “532” “533” 
“534”  
“DK221” “DK25” 
“DK26” “DK27” “DK28” 
 
   Mild liver disease “571” “57301” “57304”  
 
“DB18” “DK700” 
“DK701” “DK702” 
“DK703” “DK709” 
“DK71” “DK73” “DK74” 
“DK760” 
 
   Diabetes types 1 
and 2b 
“249” “250” 
 
“DE10” “DE11” “DE12” 
“DE13” “DE14” 
“DH360” “DO24” 
(except DO244) 
“A10A” “A10B” (except 
A10BE01) “B04AX07” 
“C10AX04” 
26 
 
Score 2    
   Hemiplegia “344”  “DG81” “DG82”  
   Moderate to 
severe renal disease 
“403” “404” “580” “581” “582” “583” 
“584” “59009” “59319” “75310” 
75311” “75319” “75320” “792”  
“DI12” “DI13” “DN00” 
“DN01” “DN02” “DN03” 
“DN04” “DN05” “DN07” 
“DN11” “DN14” “DN17” 
“DN18” “DN19” 
“DQ61” 
 
   Diabetes with end- 
organ damage  
“24901” “24902” “24903” “24904” 
“24905” “24908” “25001” “25002” 
“25003” “25004” “25005” “25008”  
“DE102” “DE103” 
“DE104” “DE105” 
“DE106” “DE107” 
“DE108” “DE112” 
“DE113” “DE114” 
“DE115” “DE116” 
“DE117” “DE118” 
“DE142” “DE143” 
“DE144” “DE145” 
“DE146” “DE147” 
“DE148” 
 
   Any tumor ”140” ”141” ”142” ”143” ”144” ”145” 
”146” ”147” ”148” ”149” ”150” ”151” 
”152” ”153” ”154” ”155” ”156” ”157” 
”158” ”159” ”160” ”161” ”162” ”163” 
”164” ”165” ”166” ”167” ”168” ”169” 
”170” ”171” ”172” ”173” ”174” ”175” 
”176” ”177” ”178” ”179” ”180” ”181” 
”182” ”183” ”184” ”185” ”186” ”187” 
”188” ”189” ”190” ”191” ”192” ”193” 
”194”  
”DC00” ”DC01” ”DC02” 
”DC03” ”DC04” ”DC05” 
”DC06” ”DC07” ”DC08” 
”DC09” ”DC10” ”DC11” 
”DC12” ”DC13” ”DC14” 
”DC15” ”DC16” ”DC17” 
”DC18” ”DC19” ”DC20” 
”DC21” ”DC22” ”DC23” 
”DC24” ”DC25” ”DC26” 
”DC27” ”DC28” ”DC29” 
”DC30” ”DC31” ”DC32” 
”DC33” ”DC34” ”DC35” 
”DC36” ”DC37” ”DC38” 
”DC39” ”DC40” ”DC41” 
”DC42” ”DC43” ”DC44” 
”DC45” ”DC46” ”DC47” 
”DC48” ”DC49” ”DC50” 
”DC51” ”DC52” ”DC53” 
”DC54” ”DC55” ”DC56” 
”DC57” ”DC58” ”DC59” 
”DC60” ”DC61” ”DC62” 
”DC63” ”DC64” ”DC65” 
”DC66” ”DC67” ”DC68” 
”DC69” ”DC70” ”DC71” 
”DC72” ”DC73 ”DC74” 
”DC75” 
 
   Leukemia ”204” ”205” ”206” ”207”  ”DC91” ”DC92” ”DC93” 
”DC94” ”DC95” 
 
   Lymphoma ”200” ”201” ”202” ”203” ”27559”  ”DC81” ”DC82” ”DC83”  
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”DC84” ”DC85” ”DC88” 
”DC90” ”DC96” 
Score 3    
   Moderate to 
severe liver disease 
“07000” “07002” “07004” “07006” 
“07008” “57300” “45600” “45601” 
“45609”  
“DB150” “DB160” 
“DB162” “DB190” 
“DK704” “DK72” 
“DK766” “DI85” 
 
Score 6    
   Metastatic solid 
tumor 
”195” ”196” ”197” ”198” ”199”  ”DC76” ”DC77” ”DC78” 
”DC79” ”DC80” 
 
   Acquired immune 
deficiency 
syndrome 
“07983”  “DB21” “DB22” “DB23” 
“DB24” 
 
Points for age 
1 point: 50-59 
years 
2 point: 60-69 
years 
3 points: 70-79 
years 
4 points: 80-89 
years 
5 points: 90-99 
years  
   
Terminal disease 
(recorded for 
partners before their 
death) 
  “DZ515” “DZ756”  
From Danish National 
Patient Registry we 
also included 
supplementary codes 
“ZNAC14” “ZPZA05.  
 
 
Prescription record for a 
terminal patient (that is, 
variable PATT with value 
“99”)   
Note: All subcodes are included unless otherwise stated. We used both A diagnoses (reasons for hospital 
contact) and B diagnoses (any other secondary/ coexisting diseases of relevance) in all cases. 
aAll ICD-10 codes in the Danish National Patient Registry begin with “D”. For example, code DI21 
represents code I21.  
bDiabetes is identified as any previous diabetes diagnosis or two or more prescriptions for antidiabetic 
medications. Women identified solely on the basis of monotherapy with metformin (A10BA02) at ages 
20–39 years were excluded, because polycystic ovarian syndrome may have been the indication for their 
prescription.   
 
 
Covariate definitions (measured prior to the index date) 
Variable Notes 
Highest attained education Defined based on the variable “hfaudd” as short (hfaudd=10), 
medium (hfaudd=20–39), or long (hfaudd=40–89). See 
Supplementary material methods 2 for more detail. 
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Study participant’s 
(conventional/non-age 
adjusted) Charlson 
Comorbidity Index score 
(grouped as low=0, 
intermediate=1–2, and 
high≥3). 
Same coding as for risk of partners’ deaths described above, 
but without age points and considering all records 5 years 
prior to the index date (including the month prior to the index 
date) 
Note: All subcodes are included unless otherwise stated; all types of contacts (inpatient, outpatient and 
emergency) were considered. Admission date was used for all variables.  
 
Outcome definitions 
Outcome 
variable 
ICD-8 ICD-10 Notes 
Chronic urticaria “708”  “DL282A” “DL50” 
“DL563” 
Excluding ICD-8 code “70890” and ICD-10 
code “DL508D”. 
 
Chronic urticaria 
and angioedema 
(for sensitivity 
analysis) 
“708”  “DL282A” “DL50” 
“DL563” “DT783” 
Excluding ICD-10 code “DL508D”. 
 
Alopecia areata “70400”  
 
“DL63” “DL65” included in sensitivity analysis (see 
table 15). 
Vitiligo “70901” “DL80” “DH027C”  
Note: We used both A diagnoses (reasons for hospital contact) and B diagnoses (any other secondary/ 
coexisting diseases of relevance) in all cases. 
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Figure S1. Illustration of follow-up periods for the study.
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Table S1. List of sensitivity analyses. 
Sensitivity analysis Justification UK Denmark 
1. Repeated main analysis restricted to individuals with 
at least 3 years of registration history in data sources 
prior to their index date. (See Table S9) 
General practitioners tend to record prevalent conditions 
when new patients register. By including individuals who 
recently registered with their general practitioner, we risk 
misclassifying prevalent outcomes as incident 
diagnoses in the study. This sensitivity analysis aimed to 
limit such misclassification. 
Yes Yes 
2. Repeated main analysis restricted to individuals 
eligible for linkage to Hospital Episode 
Statistics/Office for National Statistics death 
registration data and those who had follow-up start 
date after date of Office for National Statistics linkage 
coverage (2 January 1998). 
(See Table S10) 
Hospital admission records and more accurate death 
dates are available in linked Hospital Episode Statistics 
and Office for National Statistics data, providing more 
complete and accurate exposure and outcome data for 
this subset of patients. 
Yes No 
3. Repeated main analysis without censoring persons 
from the comparison cohort at partner bereavement, 
at transfer of their partner out of the medical practice 
(UK) or at emigration of partner (Denmark) (post-
hoc).  
(See Table S11) 
To examine data as an intention-to-treat analysis, in 
order to limit potential bias due to informative censoring 
by death or loss to follow-up of partners. 
Yes Yes 
4. Repeated main analysis after adding the end of 
partnership (separation/divorce) as a censoring 
criterion. (See Table S12) 
To examine any impact of the change in partnership 
status resulting in persons no longer being at risk of 
exposure. 
No Yes 
5. Repeated main analysis for chronic urticaria 
excluding codes that specify inducible forms (e.g., 
allergic urticarial, heat- or cold-induced urticaria), 
except cholinergic urticaria, which could be 
specifically linked to stress.  
(See Table S13) 
The codes describing inducible forms might indicate that 
chronic urticaria with other known triggers than stress. 
We excluded these codes to test the robustness of the 
outcome definition. 
Yes Yes 
6. Repeated main analysis for urticaria including codes 
for angioedema. The first recorded 
As patients with urticaria often present with 
angioedema, we included codes for angioedema to test 
Yes Yes 
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urticaria/angioedema code was defined as the 
outcome. We categorised follow-up intervals since 
the index date as 0–30 days, 0–90 days, 0–182 days, 
0–365 days, and 0–1095 days.  
(See Table S14) 
the robustness of the outcome definition. We included 
the first recorded event of angioedema as an outcome 
representing acute urticaria. 
7. Repeated main analysis for alopecia areata including 
additional codes that have non-specific descriptions 
for areata or ophiasis. (See Table S15) 
As unspecific codes might also denote alopecia areata, 
this sensitivity analysis was to test the robustness of the 
outcome definition. 
Yes Yes 
8. Repeated main analysis for vitiligo including 
additional non-specific codes for hypopigmentation.  
(See Table S16) 
As hypopigmentation could potentially represent vitiligo, 
this sensitivity analysis was performed to test the 
robustness of the outcome definition. 
Yes No 
Abbreviations: CPRD, Clinical Practice Research Datalink; HES, Hospital Episodes Statistics; ONS, the Office for National Statistic
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Figure S2. Flowcharts for inclusion in the UK and Denmark cohorts.  
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Table S2. Characteristics of the bereaved cohort and the matched comparison cohort, UK (1997-2017) and Denmark (1997-
2016). 
 The UK, No. (%) Denmark, No. (%) 
 Chronic urticaria Alopecia areata Vitiligo Chronic urticaria Alopecia areata Vitiligo 
Bereaved 
cohort 
Comparison 
cohorta 
Bereaved 
cohort 
Comparison 
cohortb 
Bereaved 
cohort 
Comparison 
cohortc 
Bereaved 
cohort 
Comparison 
cohorta 
Bereaved 
cohort 
Comparison 
cohortb 
Bereaved 
cohort 
Comparison 
cohortc 
Total 163,855 
(9.9) 
1,486,638 
(90.1) 
169,525 
(9.6) 
1,590,276 
(90.4) 
170,849 
(9.6) 
1,614,886 
(90.4) 
362,289 
(9.4) 
3,475,628 
(90.6) 
364,742 
(9.4) 
3,523,834 
(90.6) 
364,758 
(9.4) 
3,524,134 
(90.6) 
Age at index date, years       
Range 31.9-101.4 31.4-100.4 31.9-101.4 31.4-100.4 31.9-101.4 31.4-100.4 16.5-100.3 16.1-100.7 16.5-100.3 16.1-100.7 16.5-100.3 16.1-100.7 
Median 
(IQR) 
74.6  
(66.9-80.8) 
73.9  
(66.4-79.9) 
74.6  
(66.9-80.8) 
73.9  
(66.4-79.9) 
74.6  
(66.9-80.8) 
73.8  
(66.4-79.9) 
71.4  
(62.6-78.9) 
70.9  
(62.2-78.2) 
71.4  
(62.6-78.8) 
70.9  
(62.2-78.1) 
71.4  
(62.6-
78.8) 
70.9  
(62.2-78.1) 
Groups             
<50 2979  
(1.8) 
28,066  
(1.9) 
3,064  
(1.8) 
29,716  
(1.9) 
3079  
(1.8) 
30,087  
(1.9) 
24,588  
(6.8) 
243,605  
(7.0) 
24,768  
(6.8) 
247,124  
(7.0) 
24,770  
(6.8) 
247,186  
(7.0) 
50–59  15,235 
(9.3) 
146,486  
(9.9) 
15,724  
(9.3) 
156,454  
(9.8) 
15,861  
(9.3) 
158,948  
(9.8) 
46,585 
(12.9) 
462,142  
(13.3) 
46,934 
(12.9) 
468,980  
(13.3) 
46,944 
(12.9) 
469,146  
(13.3) 
60–69  37,696 
(23.0)  
361,154 
(24.3) 
39,057 
(23.0)  
387,274  
(24.4) 
39,353 
(23.0) 
393,454  
(24.4) 
92,898 
(25.6) 
922,440  
(26.5) 
93,582 
(25.7) 
935,918  
(26.6) 
93,588 
(25.7) 
936,032  
(26.6) 
70–79  61,630 
(37.6) 
585,679  
(39.4) 
63,783 
(37.6) 
627,049  
(39.4) 
64,334 
(37.7) 
637,390  
(39.5) 
120,795 
(33.3) 
1,183,992 
(34.1) 
121,561 
(33.3) 
1,199,809 
(34.0) 
121,565 
(33.3) 
1,199,833 
(34.0) 
≥80 46,315 
(28.3) 
365,253  
(24.6) 
47,897 
(28.3) 
389,783  
(24.5) 
48,222 
(28.2) 
395,007  
(24.5) 
77,423 
(21.4) 
663,449  
(19.1) 
77,897 
(21.4) 
672,003  
(19.1) 
77,891 
(21.4) 
671,937  
(19.1) 
Sex             
Women 106,648 
(65.1) 
961,405  
(64.7) 
110,746 
(65.3) 
1,036,152 
(65.2) 
111,989 
(65.6) 
1,059,373 
(65.6) 
241,680 
(66.7) 
2,314,753 
(66.6) 
243,429 
(66.7) 
2,349,052 
(66.7) 
243,443 
(66.7) 
2,349,372 
(66.7) 
Comorbidity burdend       
Mild 
 71,883 
(43.9) 
683,358  
(46.0) 
 73,867 
(43.6) 
725,417  
(45.6) 
 74,420 
(43.6) 
735,679  
(45.6) 
256,958 
(70.9) 
2,533,079 
(72.9) 
258,393 
(70.8) 
2,565,216 
(72.8) 
258,406 
(70.8) 
2,565,483 
(72.8) 
Moderate 
59,994 
(36.6) 
533,377  
(35.9) 
62,288 
(36.7) 
572,723  
(36.0) 
62,756 
(36.7) 
582,122  
(36.1) 
87,482 
(24.1) 
787,135  
(22.6) 
88,280 
(24.2) 
800,054  
(22.7) 
88,283 
(24.2) 
800,076  
(22.7) 
Severe 
31,978 
(19.5) 
269,903  
(18.2) 
33,370 
(19.7) 
292,136  
(18.4) 
33,673 
(19.7) 
297,085  
(18.4) 
17,849  
(4.9) 
155,414  
(4.5) 
18,069  
(5.0) 
158,564  
(4.5) 
18,069  
(5.0) 
158,575  
(4.5) 
Smoking  statuse       
Non-
smoker 
59,365 
(36.2) 
583,262 
(39.2) 
61,214 
(36.1) 
621,820 
(39.1) 
61,677 
(36.1) 
631,294 
(39.1) 
NA NA NA NA NA NA 
Ex-smoker 
66,133 
(40.4) 
614,743 
(41.4) 
68,894 
(40.6) 
662,973 
(41.7) 
69,477 
(40.7) 
673,835 
(41.7) 
NA NA NA NA NA NA 
Current 
smoker 
35,649 
(21.8) 
267,968 
(18.0) 
36,676 
(21.6) 
284,174 
(17.9) 
36,948 
(21.6) 
288,287 
(17.9) 
NA NA NA NA NA NA 
Missing 
2708 
(1.7) 
20,665 
(1.4) 
2741 
(1.6) 
21,309 
(1.3) 
2747 
(1.6) 
21,470 
(1.3) 
NA NA NA NA NA NA 
Alcohol consumptione       
Non-
drinker 
19,208 
(11.7) 
157,917 
(10.6) 
19,804 
(11.7) 
168,180 
(10.6) 
19,972 
(11.7) 
171,274 
(10.6) 
NA NA NA NA NA NA 
Ex-drinker 
21,180 
(12.9) 
171,353 
(11.5) 
22,025 
(13.0) 
184,371 
(11.6) 
22,218 
(13.0) 
187,890 
(11.6) 
NA NA NA NA NA NA 
Current 
drinker 
110,560 
(67.5) 
1,053,548 
(70.9) 
114,560 
(67.6) 
1,129,116 
(71.0) 
115,451 
(67.6) 
1,145,926 
(71.0) 
NA NA NA NA NA NA 
Missing 
12,907 
(7.9) 
103,820 
(7.0) 
13,136 
(7.8) 
108,609 
(6.8) 
13,208 
(7.7) 
109,796 
(6.8) 
NA NA NA NA NA NA 
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Body Mass Indexe       
<18.5 
kg/m2 
4085 
(2.5) 
26,340 
(1.8) 
4199 
(2.5) 
27,889 
(1.8) 
4248 
(2.5) 
28,570 
(1.8) 
NA NA NA NA NA NA 
18.5-24.9 
kg/m2 
55,751 
(34.0) 
506,330 
(34.1) 
57,613 
(34.0) 
541,165 
(34.0) 
58,121 
(34.0) 
550,099 
(34.1) 
NA NA NA NA NA NA 
25-29.9 
kg/m2 
56,807 
(34.7) 
548,764 
(36.9) 
58,877 
(34.7) 
587,725 
(37.0) 
59,274 
(34.7) 
596,208 
(36.9) 
NA NA NA NA NA NA 
≥30 kg/m2 
34,303 
(20.9) 
306,963 
(20.7) 
35,704 
(21.1) 
331,200 
(20.8) 
36,015 
(21.1) 
336,604 
(20.8) 
NA NA NA NA NA NA 
Missing 
12,909 
(7.9) 
98,241 
(6.6) 
13,132 
(7.8) 
102,297 
(6.4) 
13,191 
(7.7) 
103,405 
(6.4) 
NA NA NA NA NA NA 
Index of multiple deprivatione       
1 (least 
deprived) 
38,093 
(23.3) 
369,238  
(24.8) 
39,607 
(23.4) 
398,004  
(25.0) 
39,945 
(23.4) 
404,771  
(25.1) 
NA NA NA NA NA NA 
2 
34,100 
(20.8) 
321,566  
(21.6) 
35,327 
(20.8) 
344,763  
(21.7) 
35,589 
(20.8) 
349,826  
(21.7) 
NA NA NA NA NA NA 
3 
35,477 
(21.7) 
322,413  
(21.7) 
36,574 
(21.6) 
343,604  
(21.6) 
36,840 
(21.6) 
348,372  
(21.6) 
NA NA NA NA NA NA 
4 
31,965 
(19.5) 
274,562  
(18.5) 
32,937 
(19.4) 
291,003  
(18.3) 
33,176 
(19.4) 
295,376  
(18.3) 
NA NA NA NA NA NA 
5 (most 
deprived) 
24,220 
(14.8) 
198,859  
(13.4) 
25,080 
(14.8) 
212,902  
(13.4) 
25,299 
(14.8) 
216,541  
(13.4) 
NA NA NA NA NA NA 
Education durationf       
Short NA NA NA NA NA NA 
164,206 
(45.3) 
1,425,956 
(41.0) 
165,193 
(45.3) 
1,443,533 
(41.0) 
165,197 
(45.3) 
1,443,641 
(41.0) 
Medium NA NA NA NA NA NA 
109,353 
(30.2) 
1,117,941 
(32.2) 
110,239 
(30.2) 
1,135,224 
(32.2) 
110,241 
(30.2) 
1,135,353 
(32.2) 
Long NA NA NA NA NA NA 
43,456 
(12.0) 
561,037  
(16.1) 
43,835 
(12.0) 
570,878  
(16.2) 
43,848 
(12.0) 
570,948  
(16.2) 
Missing NA NA NA NA NA NA 
45,274 
(12.5) 
370,694  
(10.7) 
45,475 
(12.5) 
374,199  
(10.6) 
45,472 
(12.5) 
374,192  
(10.6) 
Follow-up (years)       
Total 875,386 7,615,764 901,811 8,087,071 910,002 8,215,110 2,778,742 23,908,172 2,793,638 24,175,416 2,793,919 24,178,364 
Median 
(IQR) 
4.3  
(1.8-8.1) 
4.2  
(1.8-7.6) 
4.3  
(1.8-8.0) 
4.1  
(1.8-7.5) 
4.3  
(1.8-8.1) 
4.1  
(1.8-7.5) 
6.8  
(3.1-11.7) 
5.8  
(2.5-10.4) 
6.8  
(3.1-11.7) 
5.7  
(2.5-10.4) 
6.8  
(3.1-11.7) 
5.7  
(2.5-10.4) 
Abbreviations: IQR, interquartile range; NA, not applicable 
aIn the UK comparison cohort, 18.9% (15.3% of unique individuals) experienced bereavement after the end of their follow-up. In the Danish comparison cohort, 22.7% (17.1% of 
unique individuals) experienced bereavement after the end of their follow-up. 
bIn the UK comparison cohort, 18.7% (15.1% of unique individuals) experienced bereavement after the end of their follow-up. In the Danish comparison cohort, 22.7% (17.0% of 
unique individuals) experienced bereavement after the end of their follow-up. 
cIn the UK comparison cohort, 18.7% (15.1% of unique individuals) experienced bereavement after the end of their follow-up. In the Danish comparison cohort, 22.7% (17.0% of 
unique individuals) experienced bereavement after the end of their follow-up. 
dComorbidity burden at index date was measured using the Charlson Comorbidity Index, categorised as low (0 point), moderate (1–2 points), and severe (≥3 points). 
eInformation on smoking status, alcohol consumption, body mass index, and index of multiple deprivation was not available in Denmark. 
f Information on education duration was not available in the United Kingdom.
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Figure S3. Pooled adjusted hazard ratios for the association between partner bereavement 
and chronic urticaria, alopecia areata, and vitiligo in the UK and Denmark.  
 
 
Effects that could not be estimated due to small event number were not included in pooled meta-analysis. Hazard ratios 
adjusted for Charlson Comorbidity Index scores.  
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Figure S4. Adjusted hazard ratios of the association between partner bereavement and chronic urticaria, alopecia areata, and 
vitiligo by characteristics in the UK and Denmark.  
 
Hazard ratios were adjusted for Charlson Comorbidity Index score. The risk of partner death was determined using the age-adjusted 
Charlson Comorbidity Index score (ACCI, categorized as low (0–3 points), intermediate (4–6 points), or high (≥7 points)) and presence 
of terminal disease (yes/no), respectively. 
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Table S3. Results of the main analysis of associations between partner bereavement and skin disorders in different follow-up 
time intervals, UK (1997–2017) and Denmark (1997–2016). 
 
Time since index 
date 
Bereaved cohort Matched comparators 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number of 
events 
Person-
years at 
risk 
Rate per 
1,000 
Number 
of events 
Person-
years at 
risk 
Rate 
per 
1,000 
The UK 
Chronic urticaria 
Entire follow-up 269 875,386 0.31 2483 7,615,764 0.33 0.96 (0.84-1.09) 0.96 (0.84-1.09) 0.97 (0.85-1.11) 
0–182 days d 78,004 d d 713,353 d 0.31 (0.08-1.26) 0.31 (0.08-1.28) 0.41 (0.10-1.71) 
0–365 days 20 150,221 0.13 214 1,376,313 0.16 0.88 (0.56-1.40) 0.88 (0.56-1.40) 0.96 (0.60-1.53) 
0–1095 days 85 388,765 0.22 846 3,542,326 0.24 0.93 (0.74-1.16) 0.93 (0.74-1.16) 0.95 (0.75-1.20) 
Alopecia areata 
Entire follow-up 49 901,811 0.05 525 8,087,071 0.06 0.82 (0.61-1.10) 0.81 (0.60-1.10) 0.85 (0.62-1.16) 
0–30 days d 13,817 d d 129,863 d NA NA NA 
0–90 days d 40,793 0.02 35 384,648 0.09 0.24 (0.03-1.73) 0.24 (0.03-1.74) 0.19 (0.02-1.48) 
0–365 days 8 155,369 0.05 105 1,470,901 0.07 0.69 (0.33-1.41) 0.69 (0.34-1.42) 0.73 (0.35-1.54) 
0–1095 days 26 401,742 0.06 247 3,779,874 0.07 0.91 (0.61-1.37) 0.91 (0.60-1.37) 0.91 (0.60-1.40) 
Vitiligo 
Entire follow-up 87 910,002 0.10 972 8,215,110 0.12 0.84 (0.67-1.05) 0.84 (0.67-1.05) 0.85 (0.67-1.07) 
0–30 days d 13,925 d d 131,873 d 0.55 (0.07-4.14) 0.63 (0.08-4.83) 0.80 (0.09-7.30) 
0–90 days 5 41,110 0.12 39 390,610 0.10 1.33 (0.52-3.38) 1.32 (0.52-3.37) 1.49 (0.55-4.06) 
0–365 days 23 156,584 0.15 177 1,493,648 0.12 1.30 (0.84-2.01) 1.30 (0.84-2.02) 1.32 (0.83-2.10) 
0–1095 days 54 404,936 0.13 449 3,838,367 0.12 1.18 (0.89-1.58) 1.18 (0.89-1.57) 1.20 (0.89-1.62) 
Denmark          
Chronic urticaria          
Entire follow-up 67 2,778,742 0.02 646 23,908,253 0.03 0.93 (0.72-1.20) 0.93 (0.72-1.20) 0.92 (0.70-1.20) 
0–182 days d 176,120 d d 1,684,577 d NA NA NA 
0–365 days d 345,359 d d 3,288,129 d 0.61 (0.15-2.53) 0.60 (0.14-2.50) 0.66 (0.16-2.81) 
0–1095 days 10 947,459 0.01 148 8,840,820 0.02 0.65 (0.34-1.24) 0.64 (0.34-1.22) 0.62 (0.31-1.22) 
Alopecia areata          
Entire follow-up 48 2,793,638 0.02 417 24,175,497 0.02 1.01 (0.75-1.38) 1.00 (0.74-1.36) 0.98 (0.71-1.35) 
0–30 days d 29,816 d d 288,053 d NA NA NA 
0–90 days d 88,713 d d 856,229 d NA NA NA 
0–365 days d 347,651 d d 3,333,059 d NA NA NA 
0–1095 days 16 953,497 0.02 129 8,957,716 0.01 1.23 (0.73-2.06) 1.20 (0.71-2.02) 1.14 (0.65-2.00) 
Vitiligo          
Entire follow-up 36 2,793,919 0.01 314 24,178,445 0.01 1.08 (0.76-1.53) 1.05 (0.74-1.49) 1.17 (0.82-1.68) 
0–30 days d 29,817 d d 288,077 d NA NA NA 
0–90 days d 88,717 d d 856,303 d NA NA NA 
0–365 days d 347,669 d d 3,333,348 d 0.18 (0.02-1.30) 0.16 (0.02-1.15) 0.22 (0.03-1.65) 
0–1095 days 8 953,555 0.01 128 8,958,460 0.01 0.63 (0.31-1.28) 0.59 (0.29-1.21) 0.70 (0.34-1.45) 
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Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not applicable  
aComputed using Cox regression stratified by matched set to account for matching variables of age, sex, county of residence (in Denmark) and general practice (in the UK). 
bAdjusted for Charlson Comorbidity Index scores. 
cComplete-case analysis was used to handle missing data for body mass index, smoking status and alcohol consumption (UK), and education duration (Denmark) in the fully 
adjusted model. Of note, the number of events, and person-years at risk in the bereaved and matched comparator cohorts presented in this table were calculated using the full 
cohort only. For chronic urticaria, the total number of bereaved and comparison persons was 144,748 and 1,207,774 respectively in the UK and 316,437 and 3,003,175 respectively 
in Denmark, after excluding those with missing values. For alopecia areata, the total number of bereaved and comparison persons was 150,072 and 1,298,085 respectively in the 
UK and 318,687 and 3,046,279 respectively in Denmark after excluding those with missing values. For vitiligo, the total number of bereaved and comparison persons was 151,293 
and 1,319,143 respectively in the UK and 318,706 and 3,046,587 respectively in Denmark after excluding those with missing values.  
dIn accordance with the confidentiality rules of the CPRD/Danish registries, we have not presented results where numbers of events are less than five. 
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Table S4. Subgroup analysis for chronic urticaria during the entire follow-up period, UK (1997-2017) and Denmark (1997-2016). 
Characteristics Bereaved cohort Matched comparators 
Unadjusted HR 
(95% CI)a 
Adjusted HR  
(95% CI)b 
Fully  
adjusted HR  
(95% CI)c 
Number 
of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
UK 
Age, years 
<50 2979 12 24,757 0.48 28,066 95 250,867 0.38 1.17 (0.63-2.14) 1.17 (0.64-2.14) p=0.43 1.17 (0.61-2.23) 
50–59 15,235 44 107,487 0.41 146,486 426 1,067,805 0.40 1.04 (0.76-1.43) 1.04 (0.76-1.42) 1.02 (0.73-1.42) 
60–69 37,696 90 240,649 0.37 361,154 952 2,253,539 0.42 0.86 (0.69-1.07) 0.86 (0.69-1.07) 0.91 (0.73-1.14) 
70–79 61,630 90 335,316 0.27 585,679 823 2,889,660 0.28 0.93 (0.74-1.16) 0.92 (0.73-1.16) 0.97 (0.77-1.23) 
≥80 46,315 33 167,177 0.20 365,253 187 1,153,893 0.16 1.27 (0.84-1.90) 1.31 (0.87-1.96) 1.11 (0.70-1.76) 
Sex 
Female 106,648 222 595,554 0.37 961,405 1905 4,944,695 0.39 1.01 (0.87-1.16) 1.00 (0.87-1.16) p=0.13 1.02 (0.88-1.18) 
Male 57,207 47 279,832 0.17 525,233 578 2,671,069 0.22 0.78 (0.57-1.06) 0.77 (0.57-1.05) 0.81 (0.59-1.11) 
Risk of partner death (ACCId score) 
Low  
(0–3 points) 
25,292 71 174,085 0.41 241,561 655 1,669,674 0.39 1.09 (0.85-1.40) 1.09 (0.84-1.39) p=0.37 1.14 (0.88-1.47) 
Intermediate 
(4–6 points) 
64,140 98 353,694 0.28 584,479 977 3,043,175 0.32 0.86 (0.69-1.06) 0.86 (0.69-1.06) 0.88 (0.70-1.10) 
High  
(≥7 points) 
74,423 100 347,607 0.29 660,598 851 2,902,914 0.29 0.98 (0.79-1.22) 0.98 (0.79-1.21) 0.97 (0.77-1.21) 
Risk of partner death (terminal diseasee) 
Yes 41,866 56 189,182 0.30 384,398 476 1,686,290 0.28 1.04 (0.78-1.38) 1.04 (0.78-1.38) p=0.53 1.02 (0.76-1.37) 
No 121,989 213 686,204 0.31 1,102,240 2007 5,929,474 0.34 0.94 (0.81-1.08) 0.94 (0.81-1.08) 0.96 (0.83-1.12) 
Denmark             
Age, years             
<50 24,588 f 265,049 f 243,605 f 2,630,605 f 0.97 (0.56-1.68) 0.96 (0.55-1.67) p=0.14 0.93 (0.53-1.66) 
50–59 46,585 f 477,581 f 462,142 f 4,607,889 f 1.02 (0.63-1.64) 1.01 (0.63-1.64) 1.04 (0.65-1.69) 
60–69 92,898 f 814,643 f 922,440 f 7,356,318 f 0.51 (0.29-0.92) 0.52 (0.29-0.93) 0.56 (0.31-1.01) 
70–79 120,795 f 861,584 f 1,183,992 f 6,875,173 f 1.52 (0.88-2.64) 1.55 (0.89-2.70) 1.46 (0.81-2.65) 
≥80 77,423 f 359,885 f 663,449 f 2,438,268 f 1.79 (0.55-5.88) 2.01 (0.57-7.06) 2.11 (0.37-
11.99) 
Sex             
Female 241,680 55 1,957,840 0.03 2,314,753 460 15,920,481 0.03 1.03 (0.77-1.38) 1.03 (0.77-1.37) p=0.09 1.02 (0.76-1.38) 
Male 120,609 12 820,901 0.01 1,160,875 186 7,987,772 0.02 0.65 (0.36-1.17) 0.66 (0.37-1.20) 0.65 (0.35-1.20) 
Risk of partner death (ACCId score) 
Low  
(0–3 points) 
95,075 27 902,331 0.03 938,938 290 8,417,254 0.03 0.92 (0.62-1.37) 0.92 (0.62-1.38) p=0.94 0.91 (0.61-1.37) 
Intermediate 
(4–6 points) 
172,824 22 1,240,293 0.02 1,632,576 219 10,141,055 0.02 0.90 (0.58-1.40) 0.90 (0.58-1.40) 0.94 (0.60-1.49) 
High  
(≥7 points) 
94,390 18 636,117 0.03 904,114 137 5,349,944 0.03 1.00 (0.59-1.69) 1.00 (0.59-1.69) 0.93 (0.52-1.66) 
Risk of partner death (terminal diseasee) 
Yes 82,802 13 531,259 0.02 811,148 127 4,794,775 0.03 0.94 (0.53-1.67) 0.92 (0.51-1.63) p=0.82 0.90 (0.49-1.64) 
No 279,487 54 2,247,483 0.02 2,664,480 519 19,113,478 0.03 0.93 (0.70-1.24) 0.93 (0.69-1.24) 0.92 (0.68-1.24) 
Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; HR, hazard ratio; CI, confidence interval 
40 
 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and general practice (in 
the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and rate per 1000 in the 
bereaved and matched comparator cohorts presented in this table were calculated in the full cohort for the unadjusted and adjusted models only. Adjusted 
additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status in the UK. The total number of bereaved and comparison 
persons was 144,748 and 1,207,774 respectively, after excluding patients with missing values for body mass index, alcohol consumption, and smoking status. 
Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison persons was 316,437 and 3,003,175 respectively, after 
excluding patients with missing education duration.  
dAge-adjusted Charlson Comorbidity Index scores were computed based on comorbidity recorded up to one month before the death of deceased partners. This 
index assigns 0 to 6 points to a range of chronic diseases according to their ability to predict death, with additional points given according to age. 
eAs an alternative measure for predicting partners’ deaths, records for terminal disease among partners at their time of death were identified. 
fIn cases where there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the CPRD/Danish registries.  
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Table S5. Subgroup analysis for alopecia areata during the entire follow-up period, UK (1997-2017) and Denmark (1997-2016). 
Characteristics Bereaved cohort Matched comparators 
Unadjusted HR 
(95% CI)a 
Adjusted HR  
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
UK 
Age, years 
<50 3064 5 25,527 0.20 29,716 26 264,791 0.10 1.97 (0.74-5.23) 1.98 (0.75-5.25) p=0.22 2.09 (0.77-5.67) 
50–59 15,724 12 110,408 0.11 156,454 114 1,132,491 0.10 1.06 (0.58-1.95) 1.07 (0.58-1.95) 1.08 (0.58-2.01) 
60–69 39,057 14 248,140 0.06 387,274 180 2,395,669 0.08 0.68 (0.39-1.18) 0.68 (0.39-1.18) 0.73 (0.42-1.29) 
70–79 63,783 13 345,430 0.04 627,049 149 3,069,482 0.05 0.85 (0.48-1.52) 0.85 (0.48-1.52) 0.89 (0.48-1.65) 
≥80 47,897 5 172,305 0.03 389,783 56 1,224,638 0.05 0.45 (0.17-1.16) 0.43 (0.17-1.13) 0.43 (0.17-1.14) 
Sex 
Female 110,746 43 615,155 0.07 1,036,15
2 
463 5,283,731 0.09 0.80 (0.58-1.10) 0.80 (0.58-1.10) p=0.71 0.82 (0.59-1.15) 
Male 58,779 6 286,656 0.02 554,124 62 2,803,340 0.02 0.94 (0.40-2.20) 0.95 (0.41-2.22) 1.07 (0.45-2.55) 
Risk of partner death (ACCId (score) 
Low  
(0–3 points) 
26,024 15 178,650 0.08 256,054      138 1,760,207 0.08 1.04 (0.61-1.79) 1.04 (0.61-1.79) p=0.59 1.08 (0.61-1.91) 
Intermediate 
(4–6 points) 
66,178 18 363,742 0.05 622,579 192 3,222,801 0.06 0.76 (0.46-1.24) 0.76 (0.46-1.24) 0.78 (0.47-1.30) 
High  
(≥7 points) 
77,323 16 359,419 0.04 711,643 195 3,104,063 0.06 0.73 (0.44-1.23) 0.72 (0.43-1.21) 0.78 (0.46-1.31) 
Risk of partner death (terminal diseasee) 
Yes 43,572 11 196,172 0.06 415,694 121 1,810,408 0.07 0.85 (0.46-1.59) 0.85 (0.46-1.59) p=0.87 0.87 (0.46-1.64) 
No 125,953 38 705,638 0.05 1,174,58
2 
404 6,276,663 0.06 0.81 (0.57-1.13) 0.80 (0.57-1.13) 0.84 (0.59-1.20) 
Denmark             
Age, years             
<50 24,768 f 266,504 f 247,124 f 2,659,624 f 1.08 (0.52-2.23) 1.05 (0.50-2.19) p=0.32 1.07 (0.50-2.29) 
50–59 46,934 f 480,442 f 468,980 f 4,661,989 f 0.59 (0.29-1.21) 0.57 (0.28-1.17) 0.48 (0.22-1.05) 
60–69 93,582 f 819,237 f 935,918 f 7,440,925 f 1.18 (0.72-1.92) 1.18 (0.73-1.93) 1.24 (0.74-2.06) 
70–79 121,561 f 865,743 f 1,199,80
9 
f 6,947,619 f 1.22 (0.62-2.41) 1.21 (0.61-2.39) 1.18 (0.57-2.45) 
≥80 77,897 f 361,712 f 672,003 f 2,465,341 f 2.93 (0.53-
16.10) 
3.86 (0.56-
26.86) 
3.67 (0.13-
100.76) 
Sex             
Female 243,429 42 1,969,049 0.02 2,349,05
2 
363 16,111,007 0.02 1.00 (0.72-1.38) 0.99 (0.71-1.37) p=0.85 0.96 (0.68-1.36) 
Male 121,313 6 824,589 0.01 1,174,78
2 
54 8,064,491 0.01 1.16 (0.50-2.72) 1.16 (0.49-2.73) 1.16 (0.49-2.75) 
Risk of partner death (ACCId score) 
Low  
(0–3 points) 
95,688 16 906,973 0.02 951,226 171 8,505,008 0.02 0.88 (0.53-1.47) 0.92 (0.54-1.54) p=0.54 0.94 (0.55-1.62) 
Intermediate 
(4–6 points) 
173,923 23 1,246,555 0.02 1,654,30
2 
160 10,252,423 0.02 1.24 (0.79-1.96) 1.23 (0.78-1.94) 1.13 (0.69-1.83) 
High  95,131 9 640,110 0.01 918,306 86 5,418,065 0.02 0.86 (0.43-1.73) 0.81 (0.41-1.64) 0.86 (0.42-1.73) 
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(≥7 points) 
Risk of partner death (terminal diseasee) 
Yes 83,492 8 534,756 0.01 824,609 84 4,859,549 0.02 0.87 (0.42-1.80) 0.88 (0.42-1.81) p=0.70 0.87 (0.42-1.82) 
No 281,250 40 2,258,881 0.02 2,699,22
5 
333 19,315,948 0.02 1.05 (0.75-1.47) 1.02 (0.73-1.44) 0.99 (0.69-1.42) 
Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and general practice (in 
the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and rate per 1000 in the 
bereaved and matched comparator cohorts presented in this table were calculated in the full cohort for the unadjusted and adjusted models only. Adjusted 
additionally for smoking status, body mass index, alcohol consumption and socioeconomic status in the UK. The total number of bereaved and comparison 
persons was 150,072 and 1,298,085, respectively, after excluding patients with missing values for body mass index, alcohol consumption, and smoking status. 
Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison persons was 318,687 and 3,046,279, respectively, after 
excluding patients with missing education duration. 
dAge-adjusted Charlson Comorbidity Index scores were computed based on comorbidity recorded up to one month before the death of deceased partners. This 
index assigns 0 to 6 points to a range of chronic diseases according to their ability to predict death, with additional points given according to age. 
eAs an alternative measure for predicting partners’ death, records for terminal disease among partners at their time of death were identified.  
fIn cases where there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the CPRD/Danish registries. 
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Table S6. Subgroup analysis for vitiligo during the entire follow-up period, UK (1997-2017) and Denmark (1997-2016). 
Characteristics Bereaved cohort Matched comparators 
Unadjusted HR 
(95% CI)a 
Adjusted HR  
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of 
persons 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
UK 
Age, years 
<50 3079 f 25,739 f 30,087 f 268,485 f 0.67 (0.20-2.17) 0.67 (0.20-2.17) p=0.40 0.72 (0.22-2.37) 
50–59 15,861 f 111,645 f 158,948 f 1,151,651 f 0.57 (0.32-0.99) 0.57 (0.32-1.00) 0.61 (0.35-1.07) 
60–69 39,353 f 250,206 f 393,454 f 2,434,484 f 0.86 (0.60-1.24) 0.86 (0.59-1.24) 0.87 (0.59-1.28) 
70–79 64,334 f 348,896 f 637,390 f 3,120,542 f 0.94 (0.64-1.40) 0.94 (0.64-1.39) 0.96 (0.64-1.44) 
≥80 48,222 f 173,516 f 395,007 f 1,239,948 f 1.36 (0.66-2.80) 1.35 (0.65-2.79) 1.17 (0.51-2.68) 
Sex 
Female 111,989 66 622,971 0.11 1,059,373 612 5,404,679 0.11 0.99 (0.76-1.28) 0.99 (0.76-1.28) p=0.03 1.01 (0.77-1.32) 
Male 58,860 21 287,031 0.07 555,513 359 2,810,431 0.13 0.57 (0.37-0.90) 0.57 (0.37-0.89) 0.56 (0.35-0.90) 
Risk of partner death (ACCId score) 
Low  
(0–3 points) 
26,193 22 180,103 0.12 259,431 298 1,784,612 0.17 0.75 (0.48-1.16) 0.75 (0.48-1.16) p=0.76 0.77 (0.49-1.21) 
Intermediate 
(4–6 points) 
66,634 35 366,742 0.10 631,294 331 3,272,011 0.10 0.92 (0.64-1.32) 0.92 (0.64-1.32) 0.93 (0.64-1.35) 
High  
(≥7 points) 
78,022 30 363,157 0.08 724,161 342 3,158,487 0.11 0.83 (0.57-1.22) 0.83 (0.57-1.22) 0.84 (0.56-1.24) 
Risk of partner death (terminal diseasee) 
Yes 43,949 27 198,054 0.14 422,759 251 1,840,666 0.14 1.01 (0.68-1.51) 1.01 (0.67-1.51) p=0.30 1.06 (0.70-1.61) 
No 126,900 60 711,948 0.08 1,192,127 720 6,374,444 0.11 0.78 (0.60-1.02) 0.78 (0.60-1.02) 0.78 (0.59-1.03) 
Denmark             
Age, years             
<50 24,770 f 266,589 f 247,186 f 2,660,549 0.02 0.55 (0.17-1.78) 0.50 (0.15-1.65) p=0.28 0.53 (0.16-1.78) 
50–59 46,944 8 480,532 0.02 469,146 89 4,663,566 0.02 0.87 (0.42-1.80) 0.82 (0.39-1.73) 0.92 (0.43-1.96) 
60–69 93,588 15 819,302 0.02 936,032 85 7,441,948 0.01 1.63 (0.93-2.86) 1.65 (0.94-2.89) 1.75 (0.99-3.10) 
70–79 121,565 6 865,810 0.01 1,199,833 60 6,947,485 0.01 0.90 (0.38-2.10) 0.89 (0.38-2.10) 0.96 (0.40-2.28) 
≥80 77,891 f 361,686 f 671,937 f 2,464,898 0.01 1.73 (0.55-5.47) 1.61 (0.50-5.23) 7.25 (0.61-
86.29) 
Sex             
Female 243,443 25 1,969,342 0.01 2,349,372 226 16,114,268 0.01 1.01 (0.66-1.53) 0.98 (0.64-1.49) p=0.51 1.07 (0.69-1.65) 
Male 121,315 11 824,577 0.01 1,174,762 88 8,064,177 0.01 1.28 (0.68-2.42) 1.25 (0.66-2.37) 1.40 (0.74-2.67) 
Risk of partner death (ACCId score) 
Low  
(0–3 points) 
95,702 14 907,148 0.02 951,454 140 8,506,989 0.02 0.94 (0.54-1.64) 0.92 (0.53-1.60) p=0.36 0.98 (0.56-1.73) 
Intermediate 
(4–6 points) 
173,920 11 1,246,605 0.01 1,654,263 113 10,252,408 0.01 0.91 (0.48-1.71) 0.90 (0.47-1.70) 0.95 (0.49-1.85) 
High  
(≥7 points) 
95,136 11 640,166 0.02 918,417 61 5,419,048 0.01 1.72 (0.89-3.31) 1.59 (0.82-3.09) 2.07 (1.04-4.11) 
Risk of partner death (terminal diseasee) 
Yes 83,492 f 534,804 f 824,695 f 4,860,435 f 0.81 (0.32-2.02) 0.79 (0.31-1.98) p=0.50 0.81 (0.32-2.03) 
No 281,266 f 2,259,115 f 2,699,439 f 19,318,010 f 1.14 (0.78-1.67) 1.11 (0.76-1.63) 1.27 (0.86-1.88) 
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Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and general practice (in 
the UK)]. 
bAdjusted for Charlson Comorbidity Index 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and rate per 1000 in the 
bereaved and matched comparator cohorts presented in this table were calculated in the full cohort for the unadjusted and adjusted models only. Adjusted 
additionally for smoking status, body mass index, alcohol consumption and socioeconomic status in the UK. The total number of bereaved and comparison 
persons was 151,293 and 1,319,143, respectively, after excluding patients with missing values for body mass index, alcohol consumption, and smoking status. 
Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison persons was 318,706 and 3,046,587, respectively, after 
excluding patients with missing education duration. 
dAge-adjusted Charlson Comorbidity Index scores were computed based on comorbidity recorded up to one month before the death of deceased partners. This 
index assigns 0 to 6 points to a range of chronic diseases according to their ability to predict death, with additional points given according to age. 
eAs an alternative measure for predicting partners’ death, records for terminal disease among partners at their time of death were identified. 
f In cases where there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the CPRD/Danish registries. 
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Table S7. Patterns of missing data on smoking status, body mass index, and alcohol consumption in the UK. 
 
Table 1.1. Missing data for smoking status. 
 Chronic urticaria Alopecia areata Vitiligo 
N (%) 23,373 (1.42) 24,050 (1.37) 24,217 (1.36) 
Covariates Odds ratio  
(95% CI) 
Odds ratio  
(95% CI) 
Odds ratio  
(95% CI) 
Outcome 0.87 (0.19-3.98) 0.06 (0.01-0.31) NAa 
Exposure – partner bereavement 0.91 (0.72-1.14) 0.91 (0.72-1.15) 0.91 (0.72-1.15) 
Body Mass Index    
  Underweight 1 1 1 
  Normal weight 0.65 (0.39-1.07) 0.72 (0.43-1.19) 0.69 (0.42-1.13) 
  Overweight 0.80 (0.48-1.31) 0.90 (0.55-1.50) 0.86 (0.52-1.41) 
  Obese 0.76 (0.46-1.27) 0.89 (0.53-1.50) 0.83 (0.50-1.39) 
Socioeconomic status    
  1 (least deprived) 1 1 1 
  2 0.88 (0.61-1.29) 0.95 (0.65-1.39) 0.94 (0.65-1.35) 
  3 0.66 (0.44-1.00) 0.67 (0.44-1.01) 0.63 (0.42-0.95) 
  4 0.58 (0.38-0.90) 0.62 (0.40-0.95) 0.58 (0.38-0.88) 
  5 (most deprived) 0.55 (0.30-1.02) 0.54 (0.29-1.02) 0.52 (0.28-0.95) 
Alcohol Status    
 Non-drinker 1 1 1 
 Current drinker 1.04 (0.81-1.34) 1.00 (0.78-1.29) 1.02 (0.79-1.31) 
 Ex-drinker 0.59 (0.43-0.82) 0.54 (0.39-0.74) 0.55 (0.40-0.76) 
Charlson Comorbidity Index score    
 Mild (score 0) 1 1 1 
 Moderate (score 1–2) 0.77 (0.65-0.91) 0.75 (0.64-0.89) 0.76 (0.64-0.89) 
 Severe (score ≥3) 0.47 (0.37-0.59) 0.47 (0.37-0.60) 0.44 (0.35-0.56) 
Abbreviations: CI, confidence interval; NA, not applicable 
Conditional logistic regression was used with the following covariates to predict the missingness of smoking status (without missingness of smoking status being 
the reference): binary outcome variable (chronic urticaria/ alopecia areata/ vitiligo), binary exposure variable (partner bereavement), body mass index, 
socioeconomic status, alcohol consumption, and Charlson Comorbidity Index score. 
aNo individual had incident vitiligo and missingness of smoking status. 
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Table 1.2. Missing data for Body Mass Index. 
 Chronic urticaria Alopecia areata Vitiligo 
N (%) 111,150 (6.73) 115,429 (6.56) 116,596 (6.53) 
Covariates Odds ratio  
(95% CI) 
Odds ratio  
(95% CI) 
Odds ratio  
(95% CI) 
Outcomes 0.35 (0.23-0.52) 0.44 (0.22-0.89) 0.27 (0.13-0.56) 
Exposure – partner bereavement 1.20 (1.16-1.23) 1.20 (1.16-1.24) 1.20 (1.16-1.24) 
Smoking status    
  Non-smoker 1 1 1 
  Current smoker 1.08 (1.05-1.11) 1.07 (1.05-1.10) 1.08 (1.05-1.11) 
  Ex-smoker 0.62 (0.60-0.63) 0.61 (0.59-0.62) 0.61 (0.60-0.63) 
Socioeconomic status    
  1 (least deprived) 1 1 1 
  2 0.92 (0.89-0.96) 0.92 (0.89-0.96) 0.92 (0.88-0.95) 
  3 0.96 (0.91-1.00) 0.94 (0.90-0.98) 0.94 (0.90-0.98) 
  4 1.01 (0.96-1.06) 1.00 (0.95-1.05) 1.00 (0.95-1.05) 
  5 (most deprived) 0.99 (0.93-1.05) 0.98 (0.92-1.04) 0.98 (0.92-1.04) 
Alcohol Status    
 Non-drinker 1 1 1 
 Current drinker 0.56 (0.55-0.58) 0.56 (0.55-0.58) 0.57 (0.55-0.58) 
 Ex-drinker 0.34 (0.33-0.36) 0.33 (0.32-0.35) 0.34 (0.32-0.35) 
Charlson Comorbidity Index 
score 
   
 Mild (score 0) 1 1 1 
 Moderate (score 1–2) 0.69 (0.67-0.70) 0.68 (0.67-0.70) 0.69 (0.67-0.70) 
 Severe (score ≥3) 0.55 (0.53-0.57) 0.55 (0.53-0.57) 0.55 (0.53-0.56) 
Abbreviations: CI, confidence interval 
Conditional logistic regression was used with the following covariates to predict the missingness of body mass index (without missingness of body mass index 
being the reference): binary outcome variable (chronic urticaria/ alopecia areata/ vitiligo), binary exposure variable (partner bereavement), smoking status, 
socioeconomic status, alcohol consumption, and Charlson Comorbidity Index score. 
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Table 1.3. Missing data for alcohol consumption 
 Chronic urticaria Alopecia areata Vitiligo 
N (%) 116,727 (7.07) 121,745 (6.92) 123,004 (6.89) 
Covariates Odds ratio (95% 
CI) 
Odds ratio (95% CI)  
Outcomes 0.90 (0.70-1.16) 1.27 (0.79-2.04) 0.92 (0.63-1.34) 
Exposure – partner bereavement 1.09 (1.06-1.13) 1.09 (1.06-1.12) 1.09 (1.06-1.13) 
Smoking status    
  Non-smoker 1 1 1 
  Current smoker 0.92 (0.89-0.94) 0.92 (0.89-0.94) 0.91 (0.89-0.94) 
  Ex-smoker 0.70 (0.68-0.71) 0.70 (0.68-0.71) 0.70 (0.68-0.71) 
Socioeconomic status    
  1 (least deprived) 1 1 1 
  2 0.98 (0.94-1.01) 0.97 (0.93-1.00) 0.98 (0.94-1.01) 
  3 1.07 (1.03-1.12) 1.08 (1.03-1.12) 1.09 (1.04-1.13) 
  4 1.08 (1.03-1.13) 1.09 (1.04-1.14) 1.09 (1.04-1.14) 
  5 (most deprived) 1.01 (0.95-1.07) 1.00 (0.94-1.06) 1.00 (0.94-1.06) 
Body Mass Index    
  Underweight 1 1 1 
  Normal weight 0.58 (0.55-0.61) 0.58 (0.55-0.62) 0.58 (0.55-0.61) 
  Overweight 0.51 (0.48-0.54) 0.52 (0.49-0.55) 0.51 (0.48-0.54) 
  Obese 0.54 (0.51-0.58) 0.55 (0.52-0.58) 0.54 (0.51-0.58) 
Charlson Comorbidity Index 
score 
   
 Mild (score 0) 1 1 1 
 Moderate (score 1–2) 0.85 (0.83-0.87) 0.85 (0.83-0.87) 0.85 (0.83-0.87) 
 Severe (score ≥3) 0.76 (0.74-0.78) 0.76 (0.74-0.78) 0.76 (0.74-0.78) 
Abbreviations: CI, confidence interval 
Conditional logistic regression was used with the following covariates to predict the missingness of alcohol status (without missingness of alcohol status being the 
reference): binary outcome variable (chronic urticaria/ alopecia areata/ vitiligo), binary exposure variable (partner bereavement), smoking status, socioeconomic 
status, body mass index, and Charlson Comorbidity Index score. 
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Table S8. Hazard ratios among the whole cohort and the complete-case cohort. 
 Full cohort Complete case cohort Full cohort Complete case cohort 
UK 
Chronic urticaria Bereaved 
Cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
N 163,855 1,486,638 144,748 1,207,774 163,855 1,486,638 144,748 1,207,774 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 0.96 (0.84-1.09) 0.96 (0.84-1.10) 0.96 (0.84-1.09) 0.96 (0.84-1.10) 
0–182 days 0.31 (0.08-1.26) 0.35 (0.08-1.43) 0.31 (0.08-1.28) 0.37 (0.09-1.52) 
0–365 days 0.88 (0.56-1.40) 0.93 (0.59-1.48) 0.88 (0.56-1.40) 0.94 (0.59-1.49) 
0–1095 days 0.93 (0.74-1.16) 0.94 (0.75-1.19) 0.93 (0.74-1.16) 0.94 (0.74-1.18) 
Alopecia areata Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
N 169,525 1,590,276 150,072 1,298,085 169,525 1,590,276 150,072 1,298,085 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 0.82 (0.61-1.10) 0.87 (0.64-1.19) 0.81 (0.60-1.10) 0.87 (0.64-1.19) 
0–30 days NA NA NA NA 
0–90 days 0.24 (0.03-1.73) 0.27 (0.04-1.99) 0.24 (0.03-1.74) 0.26 (0.04-1.93) 
0–365 days 0.69 (0.33-1.41) 0.76 (0.37-1.58) 0.69 (0.34-1.42) 0.77 (0.37-1.59) 
0–1095 days 0.91 (0.61-1.37) 0.94 (0.62-1.44) 0.91 (0.60-1.37) 0.94 (0.62-1.44) 
Vitiligo Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
N 170,849 1,614,886 151,293 1,319,143 170,849 1,614,886 151,293 1,319,143 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 0.84 (0.67-1.05) 0.83 (0.66-1.04) 0.84 (0.67-1.05) 0.83 (0.66-1.04) 
0–30 days 0.55 (0.07-4.14) 0.67 (0.09-5.11) 0.63 (0.08-4.83) 0.70 (0.09-5.47) 
0–90 days 1.33 (0.52-3.38) 1.55 (0.60-4.00) 1.32 (0.52-3.37) 1.51 (0.58-3.91) 
0–365 days 1.30 (0.84-2.01) 1.24 (0.78-1.95) 1.30 (0.84-2.02) 1.24 (0.78-1.96) 
0–1095 days 1.18 (0.89-1.58) 1.15 (0.85-1.55) 1.18 (0.89-1.57) 1.15 (0.85-1.55) 
Denmark 
Chronic urticaria Bereaved 
Cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
N 362,289 3,475,628 316,437 3,003,175 363,896 3,506,721 317,904 3,030,806 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 1.01 (0.76-1.35) 0.92 (0.70-1.20) 1.01 (0.76-1.35) 0.92 (0.70-1.20) 
0–182 days NA NA NA NA 
0–365 days 0.88 (0.21-3.73) 0.60 (0.14-2.52) 0.91 (0.21-3.87) 0.60 (0.14-2.50) 
0–1095 days 0.81 (0.41-1.60) 0.62 (0.32-1.23) 0.80 (0.40-1.59) 0.61 (0.31-1.20) 
Alopecia areata Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
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N 364,742 3,523,834 318,687 3,046,279 364,742 3,523,834 318,687 3,046,279 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 1.01 (0.75-1.38) 0.96 (0.70-1.32) 1.00 (0.74-1.36) 0.95 (0.69-1.31) 
0–30 days NA NA NA NA 
0–90 days NA NA NA NA 
0–365 days NA NA NA NA 
0–1095 days 1.23 (0.73-2.06) 1.14 (0.65-1.98) 1.20 (0.71-2.02) 1.11 (0.64-1.94) 
Vitiligo Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
Bereaved 
cohort 
Matched 
comparators 
N 364,758 3,524,134 318,706 3,046,587 364,758 3,524,134 318,706 3,046,587 
Time since index date Unadjusted HR (95% CI)a Adjusted HR (95% CI)b 
Entire follow-up period 1.08 (0.76-1.53) 1.18 (0.83-1.69) 1.05 (0.74-1.49) 1.16 (0.81-1.66) 
0–30 days NA NA NA NA 
0–90 days NA NA NA NA 
0–365 days 0.18 (0.02-1.30) 0.22 (0.03-1.62) 0.16 (0.02-1.15) 0.21 (0.03-1.57) 
0–1095 days 0.63 (0.31-1.28) 0.72 (0.35-1.48) 0.59 (0.29-1.21) 0.69 (0.33-1.42) 
Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not applicable 
aComputed using Cox regression stratified by matched set to account for the matching variables [age, sex, county of residence (in Denmark) and general practice 
(in the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
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Figure S5. Assessment of the assumption of proportional hazards. 
 
Figure 4.1. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and chronic urticaria in the UK. 
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Figure 4.2. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and chronic urticaria in Denmark. 
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Figure 4.3. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and alopecia areata in the UK. 
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Figure 4.4. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and alopecia areata in Denmark. 
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Figure 4.5. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and vitiligo in the UK. 
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Figure 4.6. Log-log plot assessing the assumption of proportional hazards in the analysis of the 
association between partner bereavement and vitiligo in Denmark. 
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Table S9. Results of stratifying follow-up time since bereavement in the UK and 
Denmark. 
 UK  Denmark 
 
Unadjusted 
hazard ratio   
(95% CI) 
p-value Unadjusted 
hazard ratio   
(95% CI) 
p-value 
Chronic urticaria     
0-182 days 0.31 (0.08-1.26) 
0.26 
N/A  
183-365 days 1.12 (0.68-1.82) 0.77 (0.18-3.26)  
366-1095 days 0.94 (0.73-1.22) 0.67 (0.33-1.37)  
1095+ days 0.97 (0.83-1.14) 1.01 (0.76-1.34) 0.53 
Alopecia areata     
0-30 days NA 
0.22 
N/A  
31-90 days 0.33 (0.04-2.51) N/A  
91-365 days 0.93 (0.43-2.03) N/A  
366-1095 days 1.07 (0.65-1.76) 1.93 (1.13-3.31)  
1095+ days 0.73 (0.47-1.13) 0.93 (0.64-1.35) 0.03 
Vitiligo     
0-30 days 0.55 (0.07-4.14) 
0.02 
N/A  
31-90 days 2.05 (0.70-6.02) N/A  
91-365 days 1.30 (0.79-2.12) 0.23 (0.03-1.67)  
366-1095 days 1.11 (0.76-1.62) 0.97 (0.44-2.11)  
1095+ days 0.56 (0.39-0.81) 1.38 (0.92-2.07) 0.07 
Abbreviations: NA, not applicable; CI, confidence interval 
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Table S10. Sensitivity analysis restricted to patients with more than 3 years of registration history.  
UK 
Chronic urticaria 
Time since 
index date 
Bereaved cohort 
(N=142,981) 
Matched comparators 
(N=1,246,768) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
213 731,333 0.29 1919 6,108,974 0.31 0.92 (0.80-1.07) 0.92 (0.79-1.06) 0.94 (0.80-1.09) 
0–182 days d 68,001 d d 597,416 d 0.44 (0.11-1.81) 0.45 (0.11-1.88) 0.51 (0.12-2.19) 
0–365 days 13 130,809 0.10 171 1,150,988 0.15 0.69 (0.39-1.21) 0.69 (0.39-1.21) 0.73 (0.41-1.29) 
0–1095 days 72 336,633 0.21 675 2,944,013 0.23 0.95 (0.74-1.21) 0.94 (0.74-1.21) 0.96 (0.75-1.24) 
Alopecia areata 
Time since 
index date 
Bereaved cohort 
(N=148,303) 
Matched comparators 
(N=1,340,771) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
45 755,678 0.06 425 6,526,908 0.07 0.90 (0.66-1.24) 0.90 (0.66-1.23) 0.94 (0.68-1.30) 
0–30 days d 12,086 d d 109,467 d NA NA NA 
0–90 days d 35,672 d d 324,081 d 0.33 (0.04-2.46) 0.33 (0.05-2.48) 0.24 (0.03-2.00) 
0–365 days 8 135,635 0.06 88 1,236,678 0.07 0.81 (0.39-1.67) 0.81 (0.39-1.68) 0.84 (0.40-1.79) 
0–1095 days 25 348,775 0.07 205 3,158,594 0.06 1.05 (0.69-1.60) 1.05 (0.69-1.59) 1.03 (0.66-1.59) 
Vitiligo 
Time since 
index date 
Bereaved cohort 
(N=149,537) 
Matched comparators 
(N=1,362,668) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
66 762,938 0.09 763 6,636,547 0.11 0.78 (0.60-1.00) 0.77 (0.60-1.00) 0.78 (0.59-1.01) 
0–30 days d 12,187 d d 111,254 d NA NA NA 
0–90 days d 35,968 d d 329,379 d 0.33 (0.04-2.40) 0.31 (0.04-2.29) 0.30 (0.04-2.36) 
0–365 days 17 136,767 0.12 147 1,256,832 0.12 1.11 (0.67-1.83) 1.11 (0.67-1.84) 1.10 (0.64-1.90) 
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0–1095 days 42 351,732 0.12 364 3,210,122 0.11 1.07 (0.77-1.48) 1.07 (0.77-1.48) 1.05 (0.74-1.48) 
Denmark 
Chronic urticaria 
Time since 
index date 
Bereaved cohort 
(N=351,760) 
Matched comparators 
(N=3,262,869) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
66 2,702,189 0.02 573 22,392,702 0.03 0.97 (0.75-1.26) 0.97 (0.74-1.26) 0.96 (0.73-1.26) 
0–182 days d 171,022 d d 1,581,419 d NA NA NA 
0–365 days d 335,408 d d 3,086,616 d 0.73 (0.17-3.09) 0.72 (0.17-3.06) 0.80 (0.18-3.45) 
0–1095 days 10 920,538 0.01 126 8,296,763 0.02 0.73 (0.38-1.39) 0.70 (0.37-1.35) 0.68 (0.34-1.35) 
Alopecia areata 
Time since 
index date 
Bereaved cohort 
(N=354,133) 
Matched comparators 
(N=3,307,474) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
46 2,716,654 0.02 366 22,639,423 0.02 1.03 (0.76-1.41) 1.03 (0.75-1.42) 1.03 (0.74-1.43) 
0–30 days d 28,949 d d 270,369 d NA NA NA 
0–90 days d 86,140 d d 803,676 d NA NA NA 
0–365 days d 337,628 d d 3,128,185 d NA NA NA 
0–1095 days 15 926,392 0.02 111 8,404,920 0.01 1.26 (0.73-2.16) 1.25 (0.73-2.15) 1.16 (0.64-2.07) 
Vitiligo 
Time since 
index date 
Bereaved cohort 
(N=354,145) 
Matched comparators 
(N=3,307,708) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
33 2,716,921 0.01 288 22,641,769 0.01 1.02 (0.71-1.47) 0.99 (0.69-1.44) 1.11 (0.76-1.62) 
0–30 days d 28,950 d d 270,388 d NA NA NA 
0–90 days d 86,143 d d 803,733 d NA NA NA 
0–365 days d 337,643 d d 3,128,413 d 0.19 (0.03-1.38) 0.16 (0.02-1.18) 0.23 (0.03-1.69) 
0–1095 days 7 926,442 0.01 116 8,405,495 0.01 0.57 (0.27-1.23) 0.55 (0.25-1.18) 0.65 (0.30-1.41) 
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Abbreviations: HR, hazard ratio; NA, not applicable; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and 
rate per 1000 in the bereaved and matched comparator cohorts presented in this table were calculated for the full cohort in the unadjusted and 
adjusted models only. Adjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status in the UK. For 
chronic urticaria, the total number of bereaved and comparison individuals was 127,484 and 1,027,109, respectively, after excluding patients with 
missing values for body mass index, alcohol consumption, and smoking status. For alopecia areata, the total number of bereaved and comparison 
individuals was 132,488 and 1,109,370, respectively, after excluding patients with missing values for body mass index, alcohol consumption, and 
smoking status. For vitiligo, the total number of bereaved and comparison individuals was 133,636 and 1,128,277, respectively, after excluding 
patients with missing values for body mass index, alcohol consumption, and smoking status. Adjusted for education duration in Denmark. For 
chronic urticaria, the total number of bereaved and comparison subjects was 307,254 and 2,822,035 respectively after excluding patients with 
missing education duration. For alopecia areata, the total number of bereaved and comparison subjects was 309,433 and 2,862,084 respectively 
after excluding patients with missing education duration. For vitiligo, the total number of bereaved and comparison subjects was 309,448 and 
2,862,330 respectively after excluding patients with missing education duration. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S11. Sensitivity analysis restricted to patients eligible for linkage to Hospital Episode Statistics/Office for 
National Statistics death registration data. 
Chronic urticaria 
Time since 
index date 
Bereaved cohort 
(N=97,287) 
Matched comparators 
(N=877,970) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
152 514,321 0.30 1502 4,466,821 0.34 0.89 (0.75-1.05) 0.89 (0.75-1.05) 0.92 (0.77-1.10) 
0–182 days d 46,247 d d 421,147 d 0.25 (0.03-1.79) 0.25 (0.03-1.82) 0.28 (0.04-2.14) 
0–365 days 13 89,034 0.15 133 812,581 0.16 0.91 (0.51-1.62) 0.91 (0.51-1.61) 0.95 (0.53-1.70) 
0–1095 days 45 230,248 0.20 540 2,091,492 0.26 0.77 (0.57-1.05) 0.78 (0.57-1.06) 0.83 (0.61-1.13) 
Alopecia areata 
Time since 
index date 
Bereaved cohort 
(N=100,750) 
Matched comparators 
(N=940,751) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
32 530,315 0.06 300 4,752,727 0.06 0.93 (0.64-1.35) 0.92 (0.63-1.33) 0.95 (0.64-1.41) 
0–30 days d 8207 d d 76,796 d NA NA NA 
0–90 days d 24,217 d d 227,467 d 0.44 (0.06-3.27) 0.41 (0.06-3.10) 0.34 (0.04-2.66) 
0–365 days 7 92,172 0.08 63 869,907 0.07 1.02 (0.47-2.22) 1.04 (0.47-2.28) 1.17 (0.52-2.67) 
0–1095 days 19 238,144 0.08 148 2,235,791 0.07 1.10 (0.68-1.78) 1.11 (0.68-1.80) 1.08 (0.65-1.81) 
Vitiligo 
Time since 
index date 
Bereaved cohort 
(N=101,491) 
Matched comparators 
(N=954,449) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
57 534,925 0.11 636 4,823,039 0.13 0.81 (0.61-1.07) 0.81 (0.61-1.07) 0.79 (0.59-1.05) 
0–30 days d 8267 d d 77,916 d 0.81 (0.10-6.20) 0.83 (0.10-6.52) 1.26 (0.11-14.28) 
0–90 days 5 24,395 0.20 27 230,789 0.12 1.87 (0.72-4.87) 1.80 (0.69-4.71) 1.76 (0.62-5.02) 
0–365 days 14 92,853 0.15 123 882,511 0.14 1.13 (0.65-1.97) 1.13 (0.65-1.97) 1.02 (0.55-1.88) 
0–1095 days 34 239,950 0.14 295 2,268,105 0.13 1.10 (0.77-1.58) 1.10 (0.76-1.58) 1.06 (0.72-1.55) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
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aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and 
rate per 1000 in bereaved and matched comparator cohorts presented in this table were calculated for the full cohort in the unadjusted and 
adjusted models only. Adjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status. For chronic 
urticaria, the total number of bereaved and comparison individuals was 85,696 and 710,525, respectively, after excluding patients with missing 
values for body mass index, alcohol consumption, and smoking status. For alopecia areata, the total number of bereaved and comparison 
individuals was 88,943 and 765,365, respectively, after excluding those with missing values for body mass index, alcohol consumption, and 
smoking status. For vitiligo, the total number of bereaved and comparison individuals was 89,624 and 777,122, respectively, after excluding those 
with missing values for body mass index, alcohol consumption, and smoking status. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S12. Post-hoc intention-to-treat analysis that did not censor follow-up on the date of experiencing partner 
bereavement, the transfer out of practice of their partner after the index date (UK), or emigration of partner 
(Denmark). 
 
UK 
Chronic urticaria 
Time since 
index date 
Bereaved cohort 
(N=163,855) 
Matched comparators 
(N=1,486,638) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
269 875,386 0.31 2915 8,858,283 0.33 0.95 (0.84-1.08) 0.95 (0.84-1.08) 0.97 (0.85-1.11) 
0–182 days d 78,004 d d 720,219 d 0.32 (0.08-1.29) 0.32 (0.08-1.32) 0.42 (0.10-1.77) 
0–365 days 20 150,221 0.13 218 1,402,128 0.16 0.88 (0.56-1.40) 0.89 (0.56-1.40) 0.96 (0.60-1.53) 
0–1095 days 85 388,765 0.22 892 3,729,502 0.24 0.92 (0.73-1.15) 0.92 (0.73-1.15) 0.95 (0.76-1.20) 
Alopecia areata 
Time since 
index date 
Bereaved cohort 
(N=169,525) 
Matched comparators 
(N=1,590,276) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
49 901,811 0.05 568 9,399,311 0.06 0.86 (0.64-1.15) 0.86 (0.64-1.15) 0.89 (0.66-1.21) 
0–30 days d 13,817 d d 130,074 d NA NA NA 
0–90 days d 40,793 d d 386,513 d 0.24 (0.03-1.76) 0.24 (0.03-1.77) 0.20 (0.03-1.55) 
0–365 days 8 155,369 0.05 107 1,498,462 0.07 0.69 (0.33-1.41) 0.69 (0.34-1.43) 0.75 (0.36-1.57) 
0–1095 days 26 401,742 0.06 262 3,979,166 0.07 0.91 (0.60-1.36) 0.91 (0.61-1.36) 0.92 (0.60-1.40) 
Vitiligo 
Time  since 
index date 
Bereaved cohort 
(N=170,849) 
Matched comparators 
(N=1,614,886) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
87 910,002 0.10 1084 9,552,321 0.11 0.83 (0.67-1.04) 0.83 (0.67-1.04) 0.83 (0.66-1.05) 
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0–30 days d 13,925 d d 132,088 d 0.55 (0.07-4.14) 0.63 (0.08-4.83) 0.80 (0.09-7.30) 
0–90 days d 41,110 d d 392,506 d 1.33 (0.52-3.39) 1.32 (0.52-3.38) 1.49 (0.55-4.06) 
0–365 days 23 156,584 0.15 180 1,521,692 0.12 1.29 (0.84-2.00) 1.30 (0.84-2.00) 1.30 (0.82-2.07) 
0–1095 days 54 404,936 0.13 471 4,041,190 0.12 1.18 (0.89-1.57) 1.18 (0.89-1.56) 1.18 (0.87-1.59) 
Denmark 
Chronic urticaria 
Time since 
index date 
Bereaved cohort 
(N=362,289) 
Matched comparators 
(N=3,475,628) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
67 2,778,742 0.02 728 28,198,922 0.03 0.96 (0.74-1.24) 0.96 (0.74-1.23) 0.95 (0.73-1.24) 
0–182 days d 176,120 d d 1,699,065 d NA NA NA 
0–365 days d 345,359 d d 3,343,793 d 0.61 (0.15-2.56) 0.60 (0.14-2.51) 0.67 (0.16-2.84) 
0–1095 days 10 947,459 0.01 149 9,270,910 0.02 0.68 (0.36-1.29) 0.66 (0.35-1.26) 0.63 (0.32-1.25) 
Alopecia areata 
Time since 
index date 
Bereaved cohort 
(N=364,742) 
Matched comparators 
(N=3,523,834) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
48 2,793,638 0.02 466 28,513,725 0.02 1.04 (0.77-1.41) 1.03 (0.76-1.39) 1.01 (0.74-1.38) 
0–30 days d 29,816 d d 288,478 d NA NA NA 
0–90 days d 88,713 d d 859,927 d NA NA NA 
0–365 days d 347,651 d d 3,389,402 d NA NA NA 
0–1095 days 16 953,497 0.02 132 9,393,087 0.01 1.23 (0.73-2.07) 1.20 (0.71-2.03) 1.16 (0.66-2.02) 
Vitiligo 
Time since 
index date 
Bereaved cohort 
(N=364,758) 
Matched comparators 
(N=3,524,134) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
36 2,793,919 0.01 356 28,517,403 0.01 1.07 (0.76-1.52) 1.05 (0.74-1.49) 1.14 (0.80-1.63) 
0–30 days d 29,817 d d 288,502 d NA NA NA 
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0–90 days d 88,717 d d 860,001 d NA NA NA 
0–365 days d 347,669 d d 3,389,699 d 0.18 (0.03-1.31) 0.16 (0.02-1.16) 0.23 (0.03-1.66) 
0–1095 days 8 953,555 0.01 129 9,393,874 0.01 0.64 (0.31-1.30) 0.60 (0.29-1.23) 0.71 (0.34-1.46) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index 
cComplete-case analysis was used to handle missing data in the fully adjusted model. Notably, the number of events, person-years at risk, and 
rate per 1000 in the bereaved and matched comparator cohorts presented in this table were calculated for the full cohort in the unadjusted and 
adjusted models only. Adjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status in the UK. For 
chronic urticaria, the total number of bereaved and comparison individuals was 144,748 and 1,207,774, respectively, after excluding those with 
missing values for body mass index, alcohol consumption, and smoking status. For alopecia areata, the total number of bereaved and comparison 
individuals was 150,072 and 1,298,085, respectively, after excluding those with missing values for body mass index, alcohol consumption, and 
smoking status. For vitiligo, the total number of bereaved and comparison individuals was 151,293 and 1,319,143, respectively, after excluding 
those with missing values for body mass index, alcohol consumption, and smoking status. Adjusted additionally for education duration in Denmark. 
For chronic urticaria, the total number of bereaved and comparison persons was 316,437 and 3,003,175, respectively, after excluding those with 
missing education duration. For alopecia areata, the total number of bereaved and comparison persons was 318,687 and 3,046,279, respectively, 
after excluding those with missing education duration. For vitiligo, the total number of bereaved and comparison persons was 318,706 and 
3,046,587, respectively, after excluding those with missing education duration. 
dIn cases in which there were fewer than 5 patients the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S13. Sensitivity analysis of censoring at the end of partnership in Denmark. 
 
Time since 
index date 
Bereaved cohort  Matched comparators  
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number of 
events 
Person-
years at 
risk 
Rate per 
1,000 
Number 
of events 
Person-
years at 
risk 
Rate per 
1,000 
Chronic urticaria          
Entire follow-up 
period 
67 2,778,742 0.02 624 23,591,188 0.03 0.94 (0.73-1.22) 0.94 (0.73-1.22) 0.93 (0.71-1.22) 
0–182 days d 176,120 d d 1,684,140 d NA NA NA 
0–365 days d 345,359 d d 3,286,183 d 0.61 (0.15-2.53) 0.60 (0.14-2.49) 0.66 (0.16-2.81) 
0–1095 days 10 947,459 0.01 146 8,819,854 0.02 0.66 (0.35-1.26) 0.65 (0.34-1.24) 0.63 (0.32-1.24) 
Alopecia areata          
Entire follow-up 
period 
48 2,793,638 0.02 414 23,854,670 0.02 0.99 (0.73-1.35) 0.98 (0.72-1.33) 0.96 (0.70-1.33) 
0–30 days d 29,816 d d 288,042 d NA NA NA 
0–90 days d 88,713 d d 856,127 d NA NA NA 
0–365 days d 347,651 d d 3,331,079 d NA NA NA 
0–1095 days 16 953,497 0.02 129 8,936,421 0.01 1.22 (0.72-2.05) 1.19 (0.70-2.01) 1.14 (0.65-1.99) 
Vitiligo          
Entire follow-up 
period 
36 2,793,919 0.01 308 23,857,621 0.01 1.09 (0.77-1.54) 1.06 (0.74-1.50) 1.18 (0.83-1.70) 
0–30 days d 29,817 d d 288,067 d NA NA NA 
0–90 days d 88,717 d d 856,200 d NA NA NA 
0–365 days d 347,669 d d 3,331,365 d 0.18 (0.02-1.30) 0.16 (0.02-1.15) 0.22 (0.03-1.65) 
0–1095 days 8 953,555 0.01 128 8,937,150 0.01 0.62 (0.30-1.28) 0.59 (0.29-1.21) 0.70 (0.34-1.44) 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, and county of residence]. 
bAdjusted for Charlson Comorbidity Index score. 
cAdjusted additionally for education duration. For chronic urticaria, the total number of bereaved and comparison persons was 316,437 and 
3,003,175, respectively, after excluding those with missing education duration. For alopecia areata, the total number of bereaved and comparison 
persons was 318,687 and 3,046,279, respectively, after excluding those with missing education duration. For vitiligo, the total number of bereaved 
and comparison persons was 318,706 and 3,046,587, respectively, after excluding those with missing education duration. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S14. Sensitivity analysis excluding codes that specify inducible forms of urticaria. 
UK 
Time since 
index date 
Bereaved cohort 
(N=163,855) 
Matched comparators 
(N=1,486,638) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
247 875,466 0.28 2316 7,616,510 0.30 0.94 (0.82-1.08) 0.94 (0.82-1.08) 0.97 (0.84-1.11) 
0–182 days d 78,004 d d 713,353 d 0.33 (0.08-1.36) 0.34 (0.08-1.38) 0.46 (0.11-1.93) 
0–365 days 19 150,221 0.13 196 1,376,318 0.14 0.93 (0.58-1.49) 0.93 (0.58-1.48) 1.00 (0.62-1.62) 
0–1095 days 80 388,771 0.21 778 3,542,405 0.22 0.95 (0.75-1.19) 0.94 (0.75-1.19) 0.99 (0.78-1.26) 
Denmark 
Time since 
index date 
Bereaved cohort 
(N=362,289) 
Matched comparators 
(N=3,475,628) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
55 2,778,818 0.02 478 23,909,290 0.02 1.01 (0.76-1.35) 1.01 (0.76-1.35) 1.00 (0.74-1.35) 
0–182 days d 176,120 d d 1,684,577 d NA NA NA 
0–365 days d 345,359 d d 3,288,132 d 0.88 (0.21-3.73) 0.91 (0.21-3.87) 0.98 (0.22-4.38) 
0–1095 days 9 947,461 0.01 109 8,840,863 0.01 0.81 (0.41-1.60) 0.80 (0.40-1.59) 0.75 (0.36-1.55) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark), and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cAdjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status. The total number of bereaved and 
comparison individuals was 144,748 and 1,207,774, respectively, after excluding those with missing values for body mass index, alcohol 
consumption, and smoking status Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison persons 
was 316,437 and 3,003,175 respectively after excluding those with missing education duration. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S15. Sensitivity analysis including codes for angioedema. 
UK 
Time since 
index date 
Bereaved cohort 
(N=163,885) 
Matched comparators 
(N=1,486,638) 
Unadjusted 
HR (95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted HR 
(95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
2278 865,383 2.63 20,746 7,532,665 2.75 0.98 (0.93-1.02) 0.98 (0.93-1.02) 0.98 (0.94-1.03) 
0–30 days 28 13,353 2.10 347 121,390 2.86 0.75 (0.51-1.10) 0.74 (0.50-1.08) 0.69 (0.46-1.05) 
0–90 days 101 39,416 2.56 1022 359,544 2.84 0.92 (0.75-1.13) 0.92 (0.75-1.12) 0.86 (0.69-1.08) 
0–182 days 236 77,952 3.03 2047 712,859 2.87 1.07 (0.94-1.23) 1.07 (0.93-1.23) 1.07 (0.93-1.23) 
0–365 days 442 150,013 2.95 3877 1,374,488 2.82 1.05 (0.96-1.16) 1.05 (0.95-1.16) 1.04 (0.93-1.15) 
0–1095 days 1115 387,263 2.88 10,142 3,529,251 2.87 1.02 (0.96-1.08) 1.02 (0.95-1.08) 1.02 (0.96-1.09) 
Denmark 
Time since 
index date 
Bereaved cohort 
(N=362,289) 
Matched comparators 
(N=3,475,628) 
Unadjusted 
HR (95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted HR 
(95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Entire follow-up 
period 
1,558 2,771,093 0.56 13,177 23,840,103 0.55 1.03 (0.97-1.08) 1.02 (0.96-1.07) 1.02 (0.96-1.08) 
0–30 days 17 29,615 0.57 140 284,108 0.49 1.15 (0.69-1.91) 1.16 (0.70-1.93) 1.05 (0.60-1.84) 
0–90 days 50 88,114 0.57 433 844,495 0.51 1.12 (0.84-1.50) 1.11 (0.83-1.49) 1.06 (0.78-1.45) 
0–182 days 93 176,098 0.53 884 1,684,364 0.52 1.02 (0.83-1.27) 1.01 (0.82-1.26) 0.99 (0.79-1.24) 
0–365 days 188 345,272 0.54 1,730 3,287,297 0.53 1.04 (0.89-1.21) 1.03 (0.89-1.20) 1.02 (0.87-1.20) 
0–1095 days 524 946,751 0.55 4,697 8,834,402 0.53 1.05 (0.96-1.16) 1.04 (0.95-1.14) 1.03 (0.93-1.13) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cAdjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status. The total number of bereaved and 
comparison individuals was 144,748 and 1,207,774, respectively, after excluding those with missing values for body mass index, alcohol 
consumption, and smoking status. Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison 
persons was 316,437 and 3,003,175, respectively, after excluding those with missing education duration. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries. 
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Table S16. Sensitivity analysis including additional non-specific codes for alopecia areata. 
UK 
Time since 
index date 
Bereaved cohort 
(N=169,525) 
Matched comparators 
(N=1,590,276) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of events 
Person-
years at 
risk 
Rate per 
1,000 
Entire follow-up 429 901,811 0.48 4321 8,087,071 0.53 0.89 (0.81-0.99) 0.89 (0.80-0.98) 0.86 (0.77-0.96) 
0–30 days d 13,817 d d 129,863 d 0.28 (0.07-1.14) 0.27 (0.07-1.11) 0.30 (0.07-1.22) 
0–90 days 8 40,793 0.20 199 384,648 0.52 0.37 (0.18-0.76) 0.37 (0.18-0.75) 0.40 (0.19-0.81) 
0–365 days 71 155,369 0.46 748 1,470,901 0.51 0.91 (0.71-1.16) 0.90 (0.71-1.16) 0.92 (0.72-1.18) 
0–1095 days 178 401,742 0.44 2028 3,779,874 0.54 0.83 (0.71-0.96) 0.82 (0.70-0.96) 0.82 (0.70-0.96) 
Denmark 
Time since 
index date 
Bereaved cohort 
(N=364,742) 
Matched comparators 
(N=3,523,834) 
Unadjusted HR 
(95% CI)a 
Adjusted HR 
(95% CI)b 
Fully adjusted 
HR (95% CI)c 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of events 
Person-
years at 
risk 
Rate per 
1,000 
Entire follow-up 48 2,793,638 0.02 417 24,175,497 0.02 1.01 (0.75-1.38) 1.00 (0.74-1.36) 0.98 (0.71-1.35) 
0–30 days d 29,816 0.00 d 288,053 d NA NA NA 
0–90 days d 88,713 d d 856,229 d NA NA NA 
0–365 days d 347,651 d d 3,333,059 d NA NA NA 
0–1095 days 16 953,497 0.02 129 8,957,716 0.01 1.23 (0.73-2.06) 1.20 (0.71-2.02) 1.14 (0.65-2.00) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
aComputed using Cox regression stratified by matched set to account for matching variables [age, sex, county of residence (in Denmark) and 
general practice (in the UK)]. 
bAdjusted for Charlson Comorbidity Index score. 
cAdjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status. The total number of bereaved and 
comparison individuals was 150,072 and 1,298,085, respectively, after excluding those with missing values for body mass index, alcohol 
consumption, and smoking status. Adjusted additionally for education duration in Denmark. The total number of bereaved and comparison 
persons was 318,687 and 3,046,279, respectively, after excluding those with missing education duration. 
dIn cases in which there were fewer than 5 patients, the exact number was withheld in accordance with the confidentiality rules of the 
CPRD/Danish registries.  
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Table S17. Sensitivity analysis including additional non-specific codes for vitiligo. 
Time since 
index date 
Bereaved cohort 
(N=170,849) 
Matched comparators 
(N=1,614,886) 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)a 
Fully adjusted 
HR (95% CI)b 
Number 
of 
events 
Person-
years at 
risk 
Rate 
per 
1,000 
Number 
of events 
Person-
years at 
risk 
Rate per 
1,000 
Entire follow-up 
period 
105 910,002 0.12 1086 8,215,110 0.13 0.91 (0.74-1.11) 0.91 (0.74-1.11) 0.93 (0.75-1.15) 
0–30 days d 13,925 d d 131,873 d 0.55 (0.07-4.14) 0.63 (0.08-4.83) 0.80 (0.09-7.30) 
0–90 days 5 41,110 0.12 41 390,610 0.10 1.26 (0.50-3.19) 1.28 (0.50-3.27) 1.43 (0.53-3.85) 
0–365 days 26 156,584 0.17 200 1,493,648 0.13 1.30 (0.86-1.95) 1.31 (0.87-1.97) 1.36 (0.88-2.10) 
0–1095 days 65 404,936 0.16 508 3,838,367 0.13 1.26 (0.97-1.64) 1.26 (0.97-1.64) 1.30 (0.99-1.71) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
aAdjusted for Charlson Comorbidity Index scores. 
bAdjusted additionally for smoking status, body mass index, alcohol consumption, and socioeconomic status. The total number of bereaved and 
comparison individuals was 151,293 and 1,319,143, respectively, after excluding those with missing values for body mass index, alcohol 
consumption and smoking status. 
